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I. INTRODUCTION 
 
         Cirrhosis derives from the Greek word meaning “tawny” and it was 
initially used to describe the gross and microscopic appearance of the chronically 
diseased and physiologically burned out and dysfunctional liver. Cirrhosis is 
fourth leading cause of death among Asian males. Cirrhosis of liver is one of the 
commonest diseases which physicians encounter both at primary as well as 
tertiary care level. Cirrhosis is a degenerative condition of the liver in which 
normal hepatic tissue is replaced by microscopically abnormal structures, which 
eventually impair liver synthetic as well as excretory function. 
            Liver cirrhosis represents the advanced stage of hepatocellular injury 
caused by chronic liver diseases such as infectious causes like hepatitis, 
alcoholic liver disease and various other causes and may gradually end in hepatic 
failure and hepatocellular carcinoma. Cirrhosis is an increasing cause of 
morbidity and mortality in more developed countries and also developing 
countries, being the 14th most common cause of death worldwide but fourth in 
central Europe. Increasingly, cirrhosis has been seen to be not a single disease 
entity, but it can be subclassified into distinct clinical prognostic stages, with 1-
year mortality ranging from 1% to 57% depending on the stage. The new 
concept in management of patients with cirrhosis should be prevention and early 
intervention to stabilize disease progression and to avoid or delay clinical 
decompensation and the need for liver transplantation. The challenge in the 21st 
century is to prevent the need for liver transplantation in as many patients with 
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cirrhosis as possible. Chronic liver disease (CLD) affects more than 29 million 
people in Europe [1] and over 300 million people worldwide. Over time, 
extracellular fibrotic tissue develops which accumulates in the liver as a result of 
chronic injury, progressively leading to fibrous septa that prevent normal hepatic 
tissue oxygenation and blood exchange to the liver parenchyma. This late stage, 
featuring marked liver anatomical changes, including extinction of hepatocytes, 
micro- and macrovascular remodeling, angioneogenesis, nodule formation and 
development of portosystemic shunts, is termed ‘cirrhosis’2. Mortality in CLD is 
primarily due to complications of liver cirrhosis and hepatocellular carcinoma 
(HCC), which is more prevalent in patients with cirrhosis when compared to 
general population. The term ‘advanced chronic liver disease’ (ACLD) ranging 
from severe fibrosis to fully developed cirrhosis. 
                    Reduced exposure to hepatitis infections also attributed to the 
declining in mortality rate from cirrhosis since 70’s. Because of doubling of 
alcoholic incidence, Scotland had high cirrhotic mortality. Worldwide cirrhosis 
contributes 8 lakh deaths because of irreversible damage to liver. Exact 
incidence rates are difficult to estimate as cirrhosis remains unnoticed until end-
stage disease has encountered. Although several treatments attempt to restrict 
further disease progression and reduce complications of cirrhosis, liver 
transplantation is the only line of permanent management option available when 
the most of the hepatocytes fail to function But even after liver transplantation, 
long-term survival of the patient is not guaranteed as graft rejection may occur. 
Because of the risk of relapse, patients with alcoholic cirrhosis are only eligible 
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for a orthotopic liver transplantation after attaining 6 months of abstinence from 
alcohol. 
              Lipids are one of the necessary components of cell wall and also which 
control cellular functions and homeostasis. Liver plays an essential role in lipid 
metabolism, as it is the major site of converting excess carbohydrate into 
triglyceride and fatty acids several stages of lipoprotein synthesis and 
transportation. The liver synthesizes large quantities of cholesterol and 
phospholipids. Majority of endogenous cholesterol is synthesized in the liver and 
its excretion by lipoprotein remnants. Synthesis and metabolism of cholesterol is 
impaired in chronic liver disease. This eventually results in decrease in plasma 
levels. High density lipoprotein (HDL) cholesterol and its major Apo 
lipoproteins have been shown to be reduced in cirrhosis, because of the severe 
metabolic derangement as also the serum levels of low‑density lipoprotein 
(LDL) cholesterol. 
                Hence this study aims at studying the changes in lipid profile in 
Cirrhosis, Thereby recommending assessment of the need for lipid profile in all 
the patients as a prognostic indicator of severity of liver cell injury. 
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                                              II. AIMS AND OBJECTIVES 
 
1. To assess the lipid profile abnormalities in patients with cirrhosis 
of liver. 
2. To correlate with the severity of cirrhosis. 
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                                         III. REVIEW OF LITERATURE 
 
 
HEPATIC ANATOMY 
 
The term liver in Greek, is the largest parenchymal organ, weighting 
approximately 1.2 - 1.5 kg and comprises one fifth of total body weight. It is 
relatively larger during infancy weighing one eighteenth of the birth weight. This 
is due mainly to left lobe of liver. The liver receives up to 25% of the total 
cardiac output
1
, indicating its major role in the metabolism like synthetic, 
excretory and detoxifying functions and its necessity for survival. Various 
metabolic and detoxifying functions are carried out by the liver. As liver is the 
major site of glycogenolysis and gluconeogenesis, the liver is involved in 
maintenance of blood glucose level during fasting states. Other metabolic 
functions include the breakdown of proteins and lipids, gluconeogenesis from 
other substrates and the synthesis of cholesterol and triglycerides. The most 
prominent detoxifying function of the liver is the biotransformation of lipophilic 
substances (Medication, nutrition additives, steroid hormones etc.) to increase 
the way for excretion.   
Liver produces daily about 500 ml of bile, and between 250 to 500 mg of 
bile acids which either lost directly through fecal route or will be temporarily 
stored in the gallbladder. Liver is responsible for detoxifying the toxins via three 
mass transport system namely blood, lymph, bile. 
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 HEPATIC BLOOD SUPPLY 
            Like few other organs in the body, the liver’s vascular system is 
composed of two supplying blood vessels, the hepatic artery and the portal vein. 
Both vessels ramify at the level of the liver hilum i.e porta hepatis in branches 
towards the right and left lobe. The hepatic artery provides the liver with 
oxygenated blood which is a branch of coeliac axis, accounting for nearly 20% 
of the total blood flow to the liver. 
Fig: 1. Anatomy of Liver 
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Fig 2: Blood supply of Liver 
 
The remaining blood supply of about 80% is delivered by the portal vein 
and contains nutrient enriched but venous blood from the intestines and spleen. 
Venous drainage of the liver is assured via the hepatic veins. When the blood 
supply to liver is compromised with reduced portal flow, the hepatic blood flow 
will increase to maintain the circulation to liver. The mechanism depends on 
local depletion of adenosine, resulting in either arterial dilation or contraction
2 
. 
The hepatic biliary tree counts two hepatic bile ducts emerging from the 
liver. Both hepatic bile ducts join together at hilum to form common bile duct, 
which transports the bile
1
. The liver also produces enormous amount of lymph, 
which is mainly produced at a cellular level (The sinusoids). So the result is, the 
liver has a deep lymphatic network for drainage of the lymph directed towards 
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the heart
3
. When sinusoidal pressure raises lymph production in Disse’s space is 
increased which plays a vital role in ascites formation in case of portal 
hypertension.  
FUNCTIONAL ANATOMY 
HEPATIC LOBULE  
Functional anatomy is now recognized only based on vascular and biliary 
anatomy. The liver lobes are classified by ‘Couinaud classification’, composed 
of repetitive anatomical units called hepatic lobules 
4
. Lobes consist of eight 
segments with I-IV segments in left lobe and V-VIII segments in right lobe. The 
hepatic lobules resemble the shape of hexagonal prisms, which are introduced by 
Kiernan in 1833. The different vessel systems are separated by approximately 
0.5 mm (5). Portal triads contain the portal vein, hepatic artery and bile duct 
(portal venule, hepatic arteriole and a bile ductile). 
HEPATIC ACINUS 
When looking from a metabolic perspective to the microcirculation, one 
of the proposed functional units is the hepatic acinus which is envisaged by 
Rappaport (6). The acinus is centered on a line connecting two terminal portal 
tracts with its terminal branch of portal vein, hepatic artery and bile duct and is 
divided in different metabolic zones. 
 
 
9 
 
Fig: 3. Hepatic Acinus 
 
 
The periportal zone I is situated closest to the arriving oxygenated blood 
flow. Therefore, zone I hepatocytes are specialized in oxidative liver functions 
(e.g. gluconeogenesis). Bridging necrosis may extend from periphery (zone I) to 
zone 3. The centrilobular zone III, on the other hand, receives blood of lesser 
quantity and thus may suffer most from ischemic injury whether viral, toxic, or 
anoxic. This region is vulnerable to ischemic damage, it still considerably helps 
in detoxification of blood. Hepatocytes contained within zone I survive longer 
because of enormous blood supply and it is the basis for liver regeneration after 
partial hepatectomy. This well architecture regenerative response of the 
hepatocytes helps them restore lost tissue up to two third of its total mass, while 
simultaneously performing vital functions to maintain the body homeostasis
7&5
. 
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SINUSOIDAL CELLS 
A liver sinusoid is a type of capillary called as, sinusoidal capillary or 
discontinuos capillary that is similar to fenestrated capillary which contains 
mixed blood from portal vein and hepatic artery. The sinusoidal cells 
(endothelial cells, Kupffer cells, hepatic stellate cells, pit cells) form a functional 
and histological unit together with sinusoidal aspect of hepatocyte. 
Plasma constituents gain access to the sub endothelial space of Disse due 
to fenestrae (approximately 0:15μm in diameter) acting as transport pores in the 
continuous endothelial lining. They act as a biofilters and transport between 
sinusoidal blood and plasma within the space of Disse. 
Fig: 4. Hepatic acinus - histology 
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The perisinusoidal space of Disse (named after German anatomist Joseph 
Disse) is situated between the hepatocytes and the sinusoids. Fenestrae have a 
dynamic cytoskeleton to preserve and control their size, which can be influenced 
by various factors like alcohol, nicotine, etc. the particle greater than 0.2 um in 
diameter which includes large triglyceride rich parent chylomicrons will not 
pass. A graded barrier is formed, retaining the macromolecules like proteins and 
RBC’s within the vascular space. In this way the fenestrae have an important 
role in chylomicron and lipoprotein metabolism. Pinocytosis, carried out by the 
endothelial cells, enables the clearance of other vital (macro) and small particles 
and denatured collagen from the circulation. The extracellular matrix may alter 
the sinusoidal capacity which is normally present, to sieve the blood particles by 
influencing the diameter of the endothelial fenestrae
5
. 
CIRRHOSIS 
Cirrhosis results from diﬀerent mechanisms of liver injury that lead to 
necroinflammation and fibrogenesis; histologically it is characterized by diﬀuse 
nodular regeneration surrounded by dense fibrotic septa with subsequent 
parenchymal extinction and collapse of liver architecture structures, together 
causing extensive distortion of hepatic vascular architecture. This distortion 
results in increased resistance to portal blood flow and hence in portal 
hypertension and in hepatic synthetic and excretary dysfunction. Clinically, 
cirrhosis has been regarded as an end-stage disease that invariably leads to death. 
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The liver is an organ that can withstand a certain degree of damage, 
because of its remarkable capacity to regenerate after injury either chemically or 
surgically. As little as 25% of the original liver mass can regenerate back to its 
full size. However, in case of cirrhosis, repeated insults to hepatocytes diffusely 
causing inflammatory changes which result in cell necrosis. As a response to 
process of necrosis, repair by fibrogenesis is activated to cooperate in the wound 
healing process. Hyperplasia of the surviving cells eventually occurs along with 
fibrosis leading to the formation of hepatocellular nodules. As hepatocyte injury 
sets in, further deterioration in hepatic functions occur. Cirrhosis tends to get 
worse by time and may even become life threatening.  
EPIDEMIOLOGY 
Cirrhosis is an increasing cause of morbidity and mortality in most of the 
developed countries. It is the 14th most common cause of death in adults 
worldwide but the fourth in central Europe; it results in 1•03 million deaths per 
year worldwide,8 170 000 per year in Europe,9 and 33 539 per year in the 
USA.10 Cirrhosis is the main  indication for 5500 liver transplants each year in 
Europe.9 The main causes in more developed countries are infection with 
hepatitis C virus, alcohol misuse, and, increasingly, non-alcoholic liver disease; 
infection with hepatitis B virus is the most common cause in sub-Saharan Africa 
and Asia. The prevalence of cirrhosis is diﬃcult to assess and probably higher 
than reported, because the initial stages are asymptomatic so it is undiagnosed. 
Prevalence was estimated at 0•3% and  the annual incidence was 15•3–132•6 per 
100 000 people in studies in the UK and Sweden. 
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Cirrhosis is characterized by fibrosis and regenerative nodules.
9  
Two 
important components of cirrhosis are, the connective tissue septa formation and 
regenerative nodules, account for the main pathophysiology of cirrhosis, 
irrespective of its etiologic starting point. Though the term cirrhosis is assumed 
to be irreversible, the prior stage fibrogenesis found to be reversible. Treating the 
underlying etiology and also with antifibrotic agents help in regression of 
cirrhosis stated in few studies. 
 ETIOLOGY 
Cirrhosis is defined as widespread fibrosis and nodule formation. In 
contrast Congenital hepatic fibrosis results in fibrosis without nodules. Partial 
nodular transformation is not a cirrhosis per se since it consists of nodules 
without fibrosis. The most common diseases lead to cirrhosis include chronic 
viral hepatitis, non-alcoholic fatty liver disease and chronic autoimmune biliary 
disease
10
. Alcoholic liver disease and hepatitis C are the predominant causes of 
cirrhosis in Western and European countries, whereas the prevalence of hepatitis 
B-induced cirrhosis is vastly increasing in developing countries. Age, sex, body 
mass index, alcohol consumption and genetic factors are often the confounding 
factors which interact with the preexisting cause. Alcohol consumption, for 
instance, may “add fuel to the fire” hastens the disease progression in HBV/HCV 
infections. 
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Fig: 5. Causes of Liver cirrhosis 
 
 
The following are various causes of Cirrhosis: 
 Alcoholic liver disease 
 Non alcoholic: 
 Viral hepatitis (A, B, C, D, E and G) 
 NASH 
 Metabolic causes 
 Haemochromatosis 
 Wilson’s disease 
 Alpha 1 - antitrypsin deficiency 
 Type IV glycogen storage diseases 
 Galactosaemia 
 Tyrosinaemia 
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Autoimmune  
 Primary biliary cirrhosis 
 Primary sclerosing cholangitis 
 Budd – Chiari syndrome 
 Heart failure- cardiac cirrhosis 
 Autoimmune hepatitis 
 Toxins and drugs e.g. methotrexate and amiodarone 
 
PATHOGENESIS 
FIBROGENESIS 
Fibrogenesis is a natural wound healing response in injured tissue. 
Fibrous scar connective tissue is produced to limit and encapsulate the damaged 
area. Sustained signals in response to repetitive hepatocellular injury result in 
excessive formation of scar tissue. Persistent accumulation of fibrosis can 
eventually lead to nodule formation which eventually cause the development of 
cirrhosis 
13,15
. 
Normal liver has a connective tissue matrix which includes type IV 
collagen, glycoproteins and proteoglycans. In case of hepatic injury, there occurs 
eightfold increase in extracellular matrix. The causative agent of hepatic injury 
can regulate the progression of fibrosis, as in congestive heart failure the fibrosis 
occurs in zone 3 and in zone 1 in bile duct obstruction and congenital hepatic 
fibrosis. In addition, factors including alcohol consumption, male gender and 
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elderly age as seen earlier are all associated with ‘rapid fibrosers’. Genetic 
determinants will also contribute to variable progression Rates
5
.  
Fig. 6. Pathogenesis of liver cirrhosis 
 
   The transition from chronic liver disease to cirrhosis involves  
 inflammation  
 activation of hepatic stellate cells with ensuing fibrogenesis 
  angiogenesis 
 parenchymal extinction lesions caused by vascular occlusion  
This process leads to pronounced hepatic microvascular changes, 
characterized by sinusoidal remodelling (extracellular matrix deposition from 
proliferating activated stellate cells resulting in capillarization of hepatic 
sinusoids), formation of intrahepatic shunts (due to angiogenesis and loss of 
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parenchymal cells) and hepatic endothelial dysfunction. The endothelial 
dysfunction is characterized by insuﬃcient release of vasodilators, of which the 
most important is nitric oxide. Release of nitric oxide is inhibited by low activity 
of endothelial nitric oxide synthetase (as a result of insuﬃcient protein-kinase-B-
dependent phosphorylation, lack of cofactors, increased scavenging resulting 
from oxidative stress and high concentrations of  endogenous inhibitors of nitric 
oxide), with concomitant increased production of vasoconstrictors (mainly 
adrenergic stimulation and thromboxane A2, but also activation of the renin-
angiotensin system, antidiuretic hormone, and endothelins).
13 
Increased hepatic resistance to portal blood flow is the primary factor 
increasing portal pressure in cirrhosis. It results from the combination of 
structural disturbances associated with advanced liver disease (accounting for 
about 70% of total hepatic vascular resistance) and of functional abnormalities 
leading to endothelial dysfunction and increased hepatic vascular tone; portal 
pressure could perhaps therefore be decreased by 30% if this functional 
abnormality were antagonised. The molecular mechanisms of these 
abnormalities are being delineated and represent new targets for therapy. 
Splanchnic vasodilation with an ensuing increase in the inflow of blood into the 
portal venous system contributes to aggravate the increase in portal pressure.
 
Splanchnic vasodilation is an adaptive response to the changes in 
intrahepatic haemodynamics in cirrhosis; its mechanisms are directly opposite to 
those of the increased hepatic vascular tone. Because of this opposition, attempts 
to correct portal hypertension by acting on hepatic resistance or portal blood 
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inflow should be ideally based on strategies acting as selectively as possible on 
the intrahepatic or the splanchnic circulation. In advanced cirrhosis, splanchnic 
vasodilation is so intense as to determine a hyperdynamic splanchnic and 
systemic circulation, which together with portal hypertension has a major role in 
the pathogenesis of ascites and hepatorenal syndrome. Systemic vasodilation 
further causes pulmonary ventilation/perfusion mismatch that in severe cases 
leads to hepatopulmonary syndrome and arterial hypoxaemia.                                       
 
Portopulmonary hypertension is characterized by pulmonary 
vasoconstriction, which is thought to be due to endothelial dysfunction in the 
pulmonary circulation. Formation and increase in size of varices is driven by 
anatomical factors, increased portal pressure and collateral blood flow, and by 
angiogenesis dependent on vascular endothelial growth factor, all of which 
contribute to variceal bleeding. Dilation of gastric mucosal vessels leads to 
portal-hypertensive gastropathy. In addition, the shunting of portal blood to the 
systemic circulation through the portosystemic collaterals is a major determinant 
of hepatic encephalopathy, of decreased first-pass eﬀect of orally administered 
drugs, and of decreased reticulo-endothelial system function. However, 
capillarisation of sinusoids and intrahepatic shunts are also major determinants 
eﬀective hepatocyte perfusion, which is a major determinant of liver failure. 
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Fig 7: Natural history of chronic liver disease 
 
 
MORPHOLOGY OF CIRRHOSIS 
Grossly with the naked eye, a cirrhotic liver appears nodular, “hub nailed” 
on the external surface and nodular on cut section. Cirrhosis can be categorized 
based on its morphology, into micronodular or macronodular variety. The most 
common one Micronodular cirrhosis implies that almost all the regenerative 
nodules are small and less than 3mm in diameter (9). It mostly seen in patients 
with injury due to hepatotoxic agent or metabolic disorder uniformly affects the 
lobules (eg.alcohol). In alcoholic liver diseases the product acetaldehyde has 
many hepatotoxic effects like inducing steatosis, increased sensitization to TNF 
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alpha mediated hepatic necrosis, forming neoantigens by various mechanisms. 
Micronodules rarely contain portal tracts or terminal hepatic veins. Cirrhotic 
macronodules consists of residual portal structures and central veins, which are 
not bound by septa. Its diameter varies from 3mm to several centimeters. 
Macronodular cirrhosis is due to viral hepatitis and arises after continued 
massive collapse of cirrhotic parenchyma, promoting accentuated regeneration
10
. 
Microscopic changes include presence of nodule and fibrous septa with 
effacement of lobular architecture. The nodules are of two types. 
i. Dissection type 
ii. Hyperplastic regenerative nodules 
Dissection nodules contains portal tracts and central veins separated by 
fibrous septa. In hypoplastic nodule no bile duct will be there which is known as 
“vanishing duct syndrome”. Although regenerative nodules are benign, it is not 
uncommon that some progress and undergo dysplastic and malignant change and 
go through carcinogenic pathway to become malignant nodules or hepatocellular 
carcinoma
17
. 
EVOLUTION OF CIRRHOSIS 
   It can be assessed on degree of fibrosis and nodule formation. Following stages 
are seen in needle biopsy 
 Incomplete septal- incomplete bridging fibrosis, no nodules 
 Early- thin bridging fibrosis and dissecting nodules 
 Moderately advanced-thick fibrosis 
 Advanced-wide septa and regenerative nodular hyperplasia 
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HEMODYNAMIC ALTERATIONS 
          Apart from complex molecular processes involved in fibrogenesis and the 
formation of regenerative nodules in cirrhosis, modifications of the 
angioarchitecture are also considered one of the important pathological views. 
These changes are necessary to convert compensated cirrhosis into 
decompensated stage. Changes are including Sinusoidal capillarization, 
neoangiogenesis and the formation of intrahepatic shunts, increase the 
intrahepatic vascular resistance leading to various complications. 
SINUSOIDAL CAPILLARIZATION 
Sinusoidal capillarization includes microcirculatory distortions in the 
liver. Sinusoidal endothelial cells play a key role in chronic liver disease 
initiation and progression , through four key processes which includes, 
sinusoidal capillarization, angiogenesis and vasoconstriction. Capillarization also 
called as dedifferentiation, occurs following liver injury. Capillarization is the 
preliminary step in the event of fibrogenesis. Liver sinusoidal endothelial cells 
(LSEC) are able to maintain hepatic stellate cells in quiescent stage as long as it 
is differentiated. So differentiated LSEC are ‘gatekeepers of fibrosis’. VEGF 
contributes mainly in maintenance of LSEC differentiation.  
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Fig. 8:Stages of cirrhosis. 
 
 
 
The cirrhotic liver reduces the number and size of the fenestrae which acts 
as barrier. The fenestrated sinusoids are thus transformed into continuous and 
more rigid capillaries (sinusoidal capillarization), which contribute further to the 
increasing intrahepatic (sinusoidal hypertension) vascular resistance and the 
subsequent development of portal hypertension. The limited permeability of the 
sinusoids deprives the hepatocytes of nutrients and hampers the ability to 
perform vital metabolic functions. Sinusoidal capillarization hence major 
contributary factor to liver failure, regardless of the metabolic capacity of 
hepatocytes. 
(18,19 & 20) 
ANGIOGENESIS AND INTRAHEPATIC SHUNTS 
In cirrhosis the main vascular abnormalities are angiogenesis 
(development of new vessels from preexisting vessels) and the presence of 
intrahepatic shunts. Both vascular abnormalities predominate along the regions 
of active inflammation and fibrous septa. Hepatic angiogenesis occurs during 
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fibrogenesis and these two processes are closely interlinked with one another. 
Liver fibrosis enhances angiogenesis and, in turn liver angiogenesis aggravates 
liver fibrosis. The vascular endothelial growth factor (VEGF) will undergo 
transcription and up regulation occurs by hepatic stellate cells to stimulate 
angiogenesis. The sustained hypoxic state when ischemia ensues in fibrotic areas 
will lead to angineogenesis to compensate the blood supply and to restore the 
hepatic blood circulation 
(21,22)
.  
The intrahepatic shunts thus impoverish the surviving parenchyma of 
nutritive blood supply, and thereby contribute to hepatocellular necrosis
10
.  The 
fibrotic processes obliterate the low pressure portal vein system, while hepatic 
arteries are high pressure system, less likely to be obliterated. As a response, the 
HABR (hepatic artery buffer response) compensatory mechanism increases the 
part of hepatic blood flow derived from the hepatic artery
23
. Arteriovenous 
anastomoses are helpful in redistributing the elevated arterial pressure to the 
portal vein and, hence contribute to portal hypertension 
10
. 
 CIRRHOTIC ANGIOARCHITECTURE 
The normal lobular angioarchitecture almost completely disappears in a 
cirrhotic liver due to persistent damage to portal fields and sinusoids. While 
chronic hepatitis lacks the presence of regenerative nodules, spatial 
disarrangements of hepatocytes and alterations of the angioarchitecture already 
appear in this earlier stage of the process toward cirrhosis. Fibrous bridges, 
connecting an enlarged portal tract and hepatic vein, contain numerous tortuous 
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and intermingled blood vessels. Portal vein branches run in parallel, of which 
only a few extend outwards into the parenchyma to give nourishment to 
hepatocytes. Those rather small veins resemble point-like inflow sources and 
provide the nutrition for liver cells to regenerate. When regenerative nodules 
become cut off from portal blood supply, hepatic artery will take over to the 
maintenance of the nodules formation and progression
5
. Another hypothesis, 
suggest that angiogenic pathways are activated within regenerative nodules to 
promote the formation of new blood vessel
10
. 
CLINICAL FEATURES AND COMPLICATIONS 
              Based on clinical terms, cirrhosis can be described as are either 
compensated or decompensated. Decompensation implies the manifestation of 
clinically evident complications resulting from either portal hypertension or liver 
insufficiency (jaundice, ascites, hepatic encephalopathy or bleeding varices). 
Ascites is usually the first sign most of the times. Hepatorenal syndrome, 
hyponatremia and spontaneous bacterial peritonitis are features of 
decompensation when it is complicated by ascites. Compensated cirrhosis, on 
the other hand, is asymptomatic almost always, as the liver is able to compensate 
for the incurred liver damage. However, it can progress to decompensation 
during the course of the time 
24
.  
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Fig 9: Clinical features 
 
SIGNS OF HEPATOCELLULAR FAILURE 
There are many clinical and pathological associations are implicated in cirrhosis. 
GASTROINTESTINAL 
Splenomegaly and abdominal wall venous collaterals are encountered in 
portal hypertension. Varices are seen in OGD scopy. Peptic ulcers has been 
found to be associated with 11% of patients. Small bowel bacterial overgrowth 
and microbial transformation accounts for 30%. Gall stones are of usually 
pigment type. Parotid enlargement and chronic pancreatitis are also seen. 
Fig 10: Portal hypertensive gastropathy & oesophageal varices 
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RENAL 
Hepatorenal syndrome is single most common association found. 
Cirrhotic glomerular sclerosis also has been found. 
FOETOR HEPATICUS 
This sweetish, slightly feculent odour of breath is due to dimethyl 
sulphide and ketones in alveolar air, which is helpful first sign in patients 
presenting in coma. 
DERMATOLOGICAL 
1. VASCULAR SPIDERS 
   Arterial spiders are found in the territory of superior vena cava and 
rarely below the line of nipples. It ranges in size from pinhead to 0.5cm in 
diameter. Vascular spider and clubbing seen in hepatopulmonary syndrome. 
Paper money skin seen in advanced cirrhosis. 
2. PALMAR ERYTHEMA 
The hands are warm and bright red in colour especially in hypothenar and 
thenar eminences and pulp of fingers. Mechanism of skin changes are due to 
estrogen excess found in liver cirrhosis. Mostly oestrodiol/ free testosterone ratio 
is highest in male cirrhotics. 
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Fig 11: Palmar erythema & spider naevi 
      
3. LEUCONYCHIA 
 These are related to hypoalbuminemia and malnutrition. 
4. DUPUYTREN’S CONTRACTURE 
 This is thickening of the palmar fascia in the hands. This may be idiopathic. 
 
Fig 12: Dupuytren’s Contracture 
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NUTRITION 
Severe malnutrition and steatorrhea are found in cirrhotic patients. 
Increased resting energy expenditure (REE) may be the factor responsible for 
this malnutrition. 
ENDOCRINE 
 HYPERGLYCEMIA 
80% of the cirrhotic patients are glucose intolerant and only 20% of them 
are diabetic. 
 HYPOGONADISM 
Diminished libido and potency are frequently seen in males. Loss of 
secondary sexual characters in males like testicular failure and in females 
premenopausal ovarian failure are common. Loss of feminine characters in 
females like pelvic pad of fat and breast tissue loss. Gynaecomastia is due to 
enlargement of glandular tissues. 
EYE SIGNS  
Lid retraction and lid lag are significantly found increased in patients. 
PORTAL HYPERTENSION 
Portal hypertension is the major complication of all type of cirrhosis and 
the primary event is obstruction or increased resistance in the portal blood flow. 
Portal venous blood bypasses the liver cells and diverted into collaterals hence 
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bypassing the detoxifying functions and is shunted directly into the hepatic 
venous radicles in the fibrous septa. 
 
Fig.13. Formation of Portal Hypertension 
 
 
These portohepatic anastomoses develop from pre - existing sinusoids 
enclosed in the septa. Even larger porto-hepatic venous anastomoses are found in 
the cirrhotic liver. About one third of the total blood flow perfusing the cirrhotic 
liver may bypass sinusoids, and so that it bypass the functioning liver tissue, 
through these channels. The obstruction to portal flow is due to nodules which 
compress hepatic venous radicles which leads to a postsinusoidal portal vein 
obstruction hence portal hypertension. However, in cirrhosis with sinusoidal 
portal hypertension, the difference between wedged hepatic venous (sinusoidal) 
pressure (WHVP) and free hepatic venous pressure (FHVP) that is hepatic 
venous pressure gradient (HVPG) i.e main portal pressures are virtually identical 
30 
 
and the stasis must extend to the portal inflow vessels. The normal HVPG is 5-
6mmHg and when it exceeds 10mmHg represents clinically significant portal 
hypertension and complications may ensue at any time with that pressure. 
Sinusoids probably provide the greatest resistance to flow. Changes in the space 
of Disse, especially collagenization, result in sinusoidal narrowing and this is 
important in the alcoholic. Portal hypertension may ensue in cirrhotic livers as a 
consequence of regenerative nodules and fibrous tissue cuddled with 
hyperdynamic circulation. Portal pressure measurement can be performed at the 
time of transjugular liver biopsy. 
ASCITES 
              Ascites is the accumulation of excessive free fluid within the peritoneal 
cavity. It is most commonly encountered first sign of decompensation in patients 
with cirrhosis. Incidence is 48% of patients. There are number of other disorders 
lead to either transudative or exudative ascites. 
PATHOGENESIS 
The accumulation of ascitic fluid represents a state of sodium and water 
retention, but the event is complex mechanism. Renal system is playing the main 
role Two widely accepted theories have been proposed. 
              First one the “Underfilling” theory or peripheral vasodilation theory 
suggests that the primary event is inappropriate sequestration of fluid within the 
splanchnic vascular bed due to sinusoidal portal hypertension and a consequent 
decrease in effective circulating blood volume. According to this theory, an 
31 
 
apparent decrease in intravascular volume (underfilling) because of peripheral 
vasodilation, is sensed by the kidney, which responds by retaining salt and water 
secondary to renin-angiotensin-aldosterone axis activation. 
             Second one the “Overflow” theory suggests that the primary abnormality 
is inappropriate renal retention of salt and secondary to hepatic insufficiency or 
sinusoidal hypertension in the absence of volume depletion. Increased 
sympathetic output results in diminished natriuresis by activation of the renin-
angiotensin system and diminished sensitivity i.e renal resistance to atrial 
natriuretic peptide. Portal hypertension plays an important role in the formation 
of ascites by increasing hydrostatic pressure within the splanchnic capillary bed 
that leads to extravasation of fluid into the third space i.e peritoneal cavity. 
Hypoalbuminemia which leading to reduced plasma oncotic pressure also favor 
the extravasation of fluid. Hence ascites is infrequent in patients with cirrhosis 
unless either or both portal hypertension and hypoalbuminemia are present. 
Hepatic lymph may seep freely from the surface of the cirrhotic liver due to 
distortion and obstruction of hepatic sinusoids and lymphatics and contribute to 
ascites formation. 
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Fig 14: Theories of ascites 
 
VARICES (COLLATERAL CIRCULATION) 
Extensive portal – systemic venous communications develop in order to 
decompress or bypass the high – pressure portal venous system. Maintenance of 
portal pressure after the collateral are formed, is attributed to a increase in 
splanchnic blood flow and splanchnic vasodilation. Splanchnic vasodilation is 
main factor in maintaining hyperdynamic circulation in cirrhosis 
 MAJOR SITES OF COLLATERALS 
 Oesophageal and gastric fundal varices (Left gastric vein, posterior gastric 
and short gastric vein join of portal system with intercostal, diaphragmo-
oesophageal and azygos veins of the caval system). 
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 Heamorrhoids (Superior haemorrhoidal vein of the portal system with 
middle and inferior haemorrhoidal veins of the caval system). 
 Caput medusa (Remnants of the umbilical circulation of the foetus present 
in the falciform ligament through a large paraumbilical vein). 
 Other sites of anastomoses are retroperitoneal vein, lumber vein and 
veins over bare area of the liver. 
VARICEAL BLEEDING 
Variceal bleeding occurs when portal venous pressure is more than 12 
mmHg in contrast varices are formed even when the portal venous pressure is 
10mmHg. Mostly bleeding arises from oesophageal varices within 3 to 5 cm of 
the oesophago-gastric junction or from gastric fundal varices. 
FACTORS PREDISPOSING TO BLEEDING 
 Large varices(>5mm diameter) 
 Endoscopic variceal stigma (cheery red spots and red wheal markings 
representing large varix) 
 High portal pressure (12mmHg) 
 Liver failure 
 Drugs (NSAIDs) 
 portal hypertensive gastropathy / coagulopathy 
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The presence of varices can be predicted by using platelet/ spleen 
diameter ratio with positive predictive value of 2.77 and negative likelihood ratio 
of 0.13. 
Fig. 15. Varices 
 
HEPATIC ENCEPHALOPATHY 
Hepatic encephalopathy is the term used to describe the complex and 
variable changes in neuropsychiatric status that complicate liver disease. In 
patients with cirrhosis, a spectrum of neuropsychiatric abnormalities exists, 
ranging from clinically indistinguishable changes in cognition to clinically 
obvious changes in the intellect, behavior, motor function and consciousness. 
Both hepatic failure and portal systemic shunts are key elements of hepatic 
encephalopathy. Principally gut derived neurotoxin, ammonia, escape the hepatic 
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metabolism and reaches the brain. This ammonia is detoxified by astrocytes in 
brain. This process results in lo grade cerebral edema, which eventually impacts 
the neural function. The hyperdynamic circulation is probably caused by an 
overproduction of nitric oxide. Hepatic encephalopathy clinically classified into 
overt and covert encephalopathy. Overt encephalopathy further claasified into 
episodic and persistent variety.  
Fig.16. Factors predisposing to Hepatic Encephalopathy 
 
 
In addition, portal hypertension results in the development of 
portosystemic collaterals. These alternative channels bypass the liver and guide a 
part of the increased portal blood flow directly into the systemic venous system 
without detoxification. Both hepatocellular failure and portosystemic shunting of 
blood play an equal role in hepatic encephalopathy
26 
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Fig.17. Management of Hepatic Encephalopathy 
 
SPONTANEOUS BACTERIAL PERITONITIS 
The most common infection in cirrhosis is spontaneous bacterial 
peritonitis (SBP). It is defined as infection of ascitic fluid in the absence of 
recognizable secondary cause of peritonitis. It is predominantly associated with 
an ascitic protein of <1gm/dL, in which case the defective opsonization of 
microorganism in ascitic fluid occurs. Spontaneous Bacterial Peritonitis (SBP) 
contributes 30% of all infections in cirrhosis and 9% of hospitalized population. 
SBP is blood borne and mostly monomicrobial. Microbial translocation is the 
key factor responsible for SBP.  
ORGANISMS 
Coliforms, Streptococci, Camphylobacter; usually infection is blood – 
borne. Ascitic fluid infection can also be due to staph. Aureus and group D 
streptococci, Enterococcus. E. coli infection is more common. Anaerobic 
bacteria are rarely found. Half patients show blood culture positivity. 
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MECHANISM 
Bacterial translocation from the gut through mesenteric node. Culture are 
more likely to be positive when 10 ml of ascetic fluid is inoculated into two 
culture bottles when the ascitic fluid protein <1gm/dl. If more than two 
organisms are identified in culture, secondary bacterial peritonitis due to surgical 
causes should be considered. 
 HEPATORENAL SYNDROME 
               The haemodynamic alteration in kidneys are due to decreased effective 
blood volume and increased sympathetic tone. Hepatorenal syndrome is the 
development of renal failure in patients with severe liver disease in the absence 
of renal parenchymal pathology. It represents the vascular and neurohumoral 
changes that occur during ascites formation. The five- year probable survival 
rate is 11%. Involvement of endothelin – 1and 3 has been implicated in 
hepatorenal syndrome. Role of nitric oxide has also been suggested as one of the 
mechanisms. 
Following six criteria must be fulfilled to encounter the diagnosis of HRS: 
 Cirrhosis with ascites 
 Serum creatinine > 1.5 mg % (>133umol/L) 
 Absence of other causes of renal failure as evidenced by proteinuria > 500 
mg/dl, urine RBC> 50/HPF and abnormal renal USG. 
 No evidence of treatment with nephrotoxic drugs/vasodilators. 
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 Absence of shock 
 Absence of sustained improvement of renal function following at least 2 
days of diuretic withdrawal and volume expansion with albumin 
(decrease in serum creatinine to 1.5mg/dl or less) 
TYPES OF HRS 
a) Type 1- rapidly progressive type over less than 2 weeks 
b) Type 2- slowly progressive type 
HEPATOPULMONARY SYNDROME 
About one third of patients with decompensated cirrhosis have been 
suffered from hepatopulmonary syndrome in the form of reduced arterial 
saturation and cyanosed. This is defined as a clinical disorder associated with 
advanced liver disease, arterial hypoxemia, pulmonary vascular dilation in the 
absence of primary cardiopulmonary disease. 
Components of Hepatopulmonary syndrome (HPS)  
 Advanced Chronic Liver Disease 
 Arterial Hypoxemia (Decreased Pao2) 
 Intra – Pulmonary Vasodilatation 
 No Primary Cardio – Pulmonary Disorder26. 
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Laboratory Evaluation  
No serologic test can diagnose cirrhosis accurately.
3
 The term liver 
function tests is a misnomer because the assays in most standard liver panels do 
not reflect the function of the liver correctly.
10
  When a liver abnormality is 
suspected, a liver panel, a complete blood count (CBC) with platelets and 
prothrombin time test should be performed.
14
 Common tests in standard liver 
panels include the serum enzymes aspartate transaminase (AST), alanine trans-
aminase (ALT), alkaline phosphatase and g-glutamyl-transferase; total, direct, 
and indirect serum bilirubin; and serum total protein and albumin. The ALT is 
thought to be the most cost-effective screening test for identifying metabolic or 
drug-induced hepatic injury. One study found that a platelet count of less than 
160 K per mm
3
 has a sensitivity of 80 percent for detecting cirrhosis in patients 
with chronic hepatitis C.
16
 
A prospective study showed a strong correlation between liver function 
test results elevated to greater than twice the upper limit of normal for at least six 
months and underlying liver disease proved by liver biopsy.
17
 Additional 
serologic studies should be pursued in such circumstances to evaluate for various 
etiologies of cirrhosis. If clinical suspicion for liver disease is high, then further 
serologic work-up is warranted within six months.
15
 If a patient has a persistently 
increased ALT level, viral hepatitis serologies should be assayed. If these are 
negative, the remaining serologic work-up should include an antinuclear 
antibodies test or anti–smooth muscle antibody test, or both, to evaluate for 
autoimmune hepatitis; and a fasting transferrin saturation level or iron-binding 
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capacity and ferritin level
18
 to evaluate for hereditary hemochromatosis.
15
 In 
patients younger than 40 years in whom Wilson’s disease is suspected, serum 
ceruloplasmin and serum and urinary copper levels should be measured. Primary 
biliary cirrhosis or primary sclerosing cholangitis should be suspected in patients 
with chronic cholestasis. Testing for a1-antitrypsin (A1AT) deficiency may be of 
benefit in patients with chronic hepatic injury and no other apparent cause. 
Ultrasonography or biopsy is necessary to establish the diagnosis of NAFLD. 
Radiographic Studies 
Although various radiographic studies may suggest the presence of 
cirrhosis, no test is considered a diagnostic standard.
3
 The major use of 
radiographic studies is to detect ascites, hepatosplenomegaly, hepatic or portal 
vein thromboses, and hepatocellular carcinoma, all of which strongly suggest the 
diagnosis of cirrhosis. 
Ultrasonography 
Abdominal ultrasonography with Doppler is a non-invasive, widely 
available modality that provides valuable information regarding the gross 
appearance of the liver and blood flow in the portal and hepatic veins in patients 
suspected to have cirrhosis. Nodularity, irregularity, increased echogenicity and 
atrophy are ultrasonographic hallmarks of cirrhosis. In advanced disease, the 
gross liver appears small and multinodular, ascites may be detected, and Doppler 
flow can be significantly decreased in the portal circulation. The discovery of 
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hepatic nodules in ultrasonography warrants further evaluation because benign 
and malignant nodules can have similar ultrasonographic appearances.
  
C T AND MRI 
CT and magnetic resonance imaging (MRI) generally are poor at 
detecting morphologic changes associated with early cirrhosis, but they can 
accurately demonstrate nodularity and lobar atrophic and hypertrophic changes, 
as well as ascites and varices in advanced disease. Although MRI sometimes 
differentiates among regener-ating or dysplastic nodules and hepatocellular 
carcinoma, it is best used as a follow-up study to determine whether lesions have 
changed in appearance and size.
20
 CT portal phase imaging can be used to assess 
portal vein patency, although flow volume and direction cannot be deter-mined 
accurately.
22
 
Although used rarely, magnetic resonance angiography (MRA) can assess 
portal hypertensive changes including flow volume and direction, as well as 
portal vein thrombosis.
22
 One study reported that MRI can accurately diagnose 
cirrhosis and provide correlation with its severity.
23
 
Liver Biopsy 
Liver biopsy is performed via percutaneous, transjugular, laparoscopic, 
open operative, or ultrasonography or CT-guided fine-needle approaches. Before 
the procedure, a CBC with platelets and prothrombin time measurement should 
be obtained. Patients should be advised to refrain from consumption of aspirin 
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and nonsteroidal anti-inflammatory drugs for seven to 10 days before the biopsy 
to minimize the risk of bleeding. 
Transient elastography (fibroscan) 
It is a non-invasive method of evaluating liver fibrosis / cirrhosis. 
LIPID METABOLISMS    
LIPID CHEMISTRY 
  Lipid constitutes a heterogenous group of components of biochemical 
importance. Its defined as compounds which are relatively insoluble in water but 
soluble in nonpolar organic solvents like benzene, chloroform, ether, alcohol and 
acetone.  Although occasionally the terms lipids and lipoids are used 
synonymously. Lipids are waxy, greasy, oily compounds of the body. In our 
human body fat serves as an efficient source of energy, except for the brain. 
Caloric value of fat is 9kcl/gm. Combination of lipids and protein (lipoprotein) 
are important cellular cytoplasmic and cell wall constituents. They form 
important dietary constituents as an account of their high calorific value and the 
fat-soluble vitamins and the essential fatty acids contained in them
28,29
. 
CHEMICAL CLASSIFICATION OF LIPIDS 
 Simple lipids 
  They are esters offatty acids with glycerol or other alcohol 
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 Compound lipids 
They are fatty acids esterified with alcohol with additional group 
(phospholipids and non-phosphorylated lipids) 
 Derived lipids  
They are derived from lipids and precursors of lipids (steroids, fatty acids) 
 Complex lipids 
FUNCTIONS OF LIPIDS  
In general lipids are important as; 
 Structure of cell membranes (phospholipids and cholesterol) 
 As ready source of energy, because lipids supply over half of the energy 
utilized in basal metabolism (trigycerides) 
 Metabolic regulators (steroid hormones and prostaglandins) 
 Act as surfactants, detergents and emulsifying agents (amphipathic lipids) 
 Gives shape and contour of the body 
 Protect internal organs by providing cushioning effect 
 Helps in absorption of fat soluble vitamins 
 Structure of sex hormones. 
 Thermal blanket, because their presence in subcutaneous tissue insulates 
the body against heat loss. 
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FATTY ACIDS 
They are included in the group of derived lipids. They are carboxylic 
acids obtained from the hydrolysis of mainly glycerol and cholesterol. They 
classified based on odd or even number of carbon atoms and depending on the 
length of hydrocarbon chain and nature of hydrocarbon chain whether it is 
saturated or unsaturated or branched chain or hydroxy fatty acids. The chain may 
be saturated (containing no double bonds) or unsaturated (containing one-mono-
unsaturated or more- poly unsaturated double bonds). The main saturated fatty 
acids are palmitic and stearic acid. 
Unsaturated fatty acids are again subdivided into: 
 Monounsaturated (mono-enoic acids). 
 Poly unsaturated (Poly-enoic acids). 
 
 Fatty acids are aliphatic carboxylic acids, and have given general formula of  
R-CO-OH. In which carboxylic acid group represents the functional group. 
Normal Values: 250-400 mg/dl. Free fatty acids are readily available source of 
energy and fulfills majority of the energy requirements in our body
28, 29
. 
CHOLESTEROL 
It was first described during the end of 18th century by French chemist 
De Fourerol. It is distributed in almost all cells of the body as a component of 
cell membrane particularly in nervous tissue. Cholesterol is the most important 
compound of those classed as sterols. It is a precursor of bile acids, the steroid 
hormones and Vitamin D. Out of total 27 carbon atoms its having one hydroxyl 
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group at the position of 3
rd
 atom. Esterification occurs at this position by 
lecithine cholesterol acyl transferase. With fatty acids, it forms waxes. It is a 
stable white crystalline substance insoluble in water but readily soluble in 
solvents like chloroform, ether, alcohol, and other fat solvents. The cholesterol is 
present in high amounts in nervous tissue (2%), liver (0.3%), skin (0.3%) and 
intestine (0.2%) and certain endocrine glands 
27&29
. 
The relative high content of the cholesterol in skin may be related to 
vitamin D formation and that in adrenals to steroid hormones synthesis and 
gonads. Much attention being directed towards cholesterol at present era, not 
only because of it is related to other steroids in the body, but also because 
cholesterol is involved in degenerative changes in the arterial wall known as 
atherosclerosis, major reason for cardiovascular mortality. 
Normal Values: Range from 160-240 mg/dl. 
 TRIGLYCERIDES (TRIACYLGLYCEROLS) 
The liver and adipose tissue are the major sites of triacylglycerol 
synthesis. Triacylglycerols, so called neutral fats, are esters of the alcohol 
glycerol and fatty acids. The TAG synthesis in adipose tissue is for storage of 
energy while in liver it is mainly secreted as VLDL and is transported. On 
hydrolysis triglycerides yield 3 fatty acid, and 1 molecule of glycerol when it is 
boiled together with an alkali saponification occurs
27 &29
. It contributes major 
component of chylomicron. 
Normal values: 40-150 mg%. 
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PHOSPHOLIPIDS 
Phospholipids are complex lipids, resembling triglycerides, but along 
with glycerol and fatty acids it also contains phosphate and a nitrogenous base. 
The major phospholipids in plasma are lecithin which is amphipathic lipid and 
sphingomyelin, the only phospholipid that contain phosphate and have no sugar 
moiety. The phosphoric acid and nitrogenous base choline are forming polar 
head which is water-soluble. Lipids since they are insoluble in water, are carried 
in the plasma in the form of lipoprotein complexes. These complexes of lipid 
and protein impart solubility, and all lipids enter and travel through the blood 
stream as lipid-protein complexes. The protein part of it is known as 
apolipoprotein. 
STRUCTURE OF A LIPOPROTEIN PARTICLE 
The lipoprotein particle contains a hydrophobic core of triglyceride and 
cholesterol ester, surrounded by a coat containing polar phospholipids, free 
cholesterol. Lipoproteins are classified by their buoyant density, which inversely 
reflects their size. The greater the lipid to protein ratio, the larger their size and 
the lower the density. Lipoproteins can be classified into five main groups. The 
first three are triglyceride rich and, because of their large size, they scatter light, 
which can give plasma a turbid appearance (lipaemic) if present in high 
concentrations: 
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            TABLE : Characteristics of major lipoproteins 
 
Lipoprotein Source Composition (% mass) Apolipoprotein Electrophoretic 
mobility Pro Cho TGL PL 
Chylomicrons Gut 1 4 90 5 A, B, C, E Origin 
VLDL Liver 8 25 55 12 B, C, E Pre-b 
LDL VLDL via IDL 20 55 5 20 B B 
HDL Gut/liver 50 20 5 25 A, C, E A 
Cho, cholesterol; HDL, high-density lipoprotein; IDL, intermediate-density 
lipoprotein; LDL, low-density lipoprotein; PL, phospholipid; Pro, protein; TGL, 
triglyceride; VLDL, very low-density lipoprotein. 
 
 Chylomicrons are the largest and least dense lipoproteins and transport 
exogenous lipid from the intestine to all cells. 
 Very low-density lipoproteins (VLDLs) transport endogenous lipid from 
the liver to cells. 
 Intermediate-density lipoproteins (IDLs), which are transient and formed 
during the conversion of VLDL to low-density lipoprotein (LDL), are 
not normally present in plasma. 
The other two lipoprotein classes contain mainly cholesterol and are smaller 
in size: 
 Low-density lipoproteins are formed from VLDLs and carry 
cholesterol to cells. 
 High-density lipoproteins (HDLs) are the most dense lipoproteins and 
are involved in the transport of cholesterol from cells back to the liver 
(reverse cholesterol transport). These lipoproteins can be further 
divided by density into HDL2 and HDL3. 
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If a lipaemic plasma sample, for example after a meal, is left overnight at 
4°C, the larger and less dense chylomicrons form a creamy layer on the surface. 
The smaller and denser VLDL and IDL particles do not rise, and the sample may 
appear diffusely turbid. The LDL and HDL particles do not contribute to this 
turbidity because they are small and do not scatter light. Fasting plasma from 
normal individuals contains only VLDL, LDL and HDL particles. 
In some cases of hyperlipidemia, the lipoprotein patterns have been 
classified (Fredrickson’s classification) according to their electrophoretic 
mobility. Four principal bands are formed, based on their relative positions, by 
protein electrophoresis, namely a (HDL), pre-b (VLDL), b (LDL) and 
chylomicrons. 
 Intermediate-density lipoproteins in excess may produce a broad b-band. 
Some individuals with hyperlipidaemia may show varying electrophoretic 
patterns at different times. Ultracentrifugation (separation based upon particle 
buoyant density) or   electrophoretic techniques are rarely used in routine clinical 
practice. Instead, the   lipoprotein composition of plasma may be inferred from 
standard clinical laboratory lipid assays. As fasting plasma does not normally 
contain chylomicrons, the triglyceride content reflects VLDL. Furthermore, 
generally about 70 per cent of plasma cholesterol is incorporated as LDL and 20 
% as HDL. The HDL particles because of  their  high  density,  can  be  
quantified  by precipitation techniques that can assay their cholesterol content by 
subtraction, although direct HDL assays are now used. 
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The Friedewald equation enables plasma LDL cholesterol concentration 
to be calculated and is used in many clinical laboratories: 
LDL cholesterol = Total cholesterol – {HDL cholesterol-TGL/5} 
This equation makes certain assumptions, like when the patient is fasting 
and the plasma triglyceride concentration does not exceed 4.5 mmol/L (otherwise 
chylomicrons make the equation inaccurate). 
 MAJOR CLASSES OF APOLIPOPROTEINS               
Table: The main apolipoproteins and their common functions 
 
Apolipoprotein Associated lipoprotein Function 
A1 Chylomicrons and HDL LCAT activator 
A2 Chylomicrons and HDL LCAT activator 
B48 Chylomicrons and VLDL Secretion of chylomicrons/VLDL 
B100 IDL, VLDL, LDL LDL receptor binding 
C2 Chylomicrons, HDL, VLDL, IDL Lipoprotein lipase activator 
C3 Chylomicrons, HDL, VLDL, IDL Lipoprotein lipase inhibitor 
E Chylomicrons, HDL, VLDL, IDL IDL and remnant particle receptor binding 
HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LCAT, 
lecithin–cholesterol acyltransferase; LDL, low-density lipoprotein; VLDL, 
very low-density lipoprotein. 
 
NORMAL LIPOPROTEIN METABOLISM 
Chylomicrons are formed from dietary fats and cholesterol absorbed in 
the Intestine by the intestinal mucosal cells. They are secreted into the lacteals of 
lymphatics, pass through the thoracic duct and eventually enter the systemic 
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circulation. Main sites of metabolism are adipose tissue and skeletal muscle. As 
chylomicron enter capillaries, they come in contact with lipoprotein lipase, an 
enzyme located on the surface of endothelial cells particularly in capillaries of 
adipose tissue and muscle. Lipoprotein lipase needs insulin for maintenance of 
its activity. The interaction of chylomicrons and lipoprotein lipase results in 
hydrolysis of triglyceride into fatty acids and glycerol following activation of 
LPL by Apo C II of chylomicron. 
LIPID TRANSPORT 
THE EXOGENOUS PATHWAY 
The dietary triglycerides and cholesterol are incorporated into large 
lipoprotein complexes, so called chylomicrons within the intestinal epithelial 
cells. Cholesterol and fatty acids released from dietary fats by digestion together 
with bile are absorbed into intestinal mucosa cells where they are re-esterified to 
form cholesterol esters and triglycerides. These together with phospholipids and 
apoA and apoB are then secreted into the lymphatic system as chylomicrons. 
This secretion is dependent upon apoB48. The chylomicrons enter the systemic 
circulation via the thoracic duct. Apolipoprotein C and apoE, both derived 
from HDL, are added to the chylomicrons in the lymph and plasma. The enzyme 
lipoprotein lipase is located on capillary walls and is activated by apoC2 and 
inhibited by apoC3. It hydrolyses triglyceride into fatty acids and glycerol. The 
former is taken up by adipose tissue or muscle cells or bound to albumin in the 
plasma. The glycerol component enters the hepatic glycolytic pathway. During 
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their travel within the circulation, the chylomicron particles get smaller and 
release some apoA and apoC along with phospholipids, which later become 
incorporated into HDL particles. The chylomicron remnants enriched in apoB 
and apoE and cholesterol then bind rapidly to hepatic LDL-receptor related 
protein, which recognizes the apoE ligand. Within the hepatic cells the cholesterol 
is utilised and the apolipoproteins catabolized. Thus, ultimately the exogenous 
pathway delivers triglyceride to adipose tissue and muscle and cholesterol to the 
liver. 
Fig. 18: Lipid transport 
 
 THE ENDOGENOUS PATHWAY 
Liver is the main source of endogenous lipids. Carbohydrates gets 
converted to fatty acids in the liver, it also esterifies the fatty acids with glycerol 
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to form triglycerides and most endogenous cholesterols getting produced in the 
liver. Hepatic cholesterols can either be derived from chylomicron remnant or 
from exogenous pathway or synthesized locally. From the liver lipids are 
transported as VLDL particles are transported to tissue capillaries. In peripheral 
tissues they are removed in the same way as chylomicrons (Hydrolysis by the 
Enzyme Lipoprotein Lipase). 
Very low-density lipoprotein is a large triglyceride- rich particle 
consisting also of apoB100, apoC and apoE. Following hepatic secretion of 
VLDL, it incorporates additional apoC from HDL particles within the 
circulation. Like chylomicrons, VLDL is hydrolysed by lipoprotein lipase in the 
peripheral tissues. The resulting VLDL remnant or intermediate density 
lipoprotein (IDL) contains cholesterol and triglyceride as well as apoB and apoE 
and is rapidly taken up by the liver or converted by the action of hepatic lipase to 
LDL by losing apoE and triglyceride. 
Low-density lipoprotein is a small cholesterol-rich lipoprotein containing 
only apoB. It constitutes about 70 % of the total plasma cholesterol concentration. 
It can be taken up by most cells, although mainly the liver by the LDL receptor 
which recognizes and binds apoB100. Within the cell, the LDL particles are 
broken down by lysosomes, releasing cholesterol. This cholesterol can be 
incorporated into cell membranes or in specific tissues such as the adrenal cortex 
or gonads and utilized in steroid synthesis. 
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  Most cells are able to synthesize cholesterol, but, to avoid intracellular 
accumulation, there is a feedback control system reducing the rate of synthesis of 
the LDL receptors. Although most of the plasma LDL is removed by LDL 
receptors, if the plasma cholesterol concentration is excessive, LDL particles, by 
virtue of their small size, can infiltrate tissues by passive diffusion and can even 
cause damage, as in atheroma formation within arterial walls. An alternative 
route of removal of LDL is via the reticuloendothelial system, collectively 
termed the scavenger cell pathway, which recognizes only oxidized LDL.  
 
 The liver has a central role in cholesterol metabolism: 
 Because liver contains most of the LDL receptors, 
 It is responsible for most of the endogenous cholesterol synthesis, 
 it takes up cholesterol from the diet via lipoproteins, 
 it can excrete cholesterol from the body in bile. 
 
 Cholesterol is synthesized via a series of enzymatic steps, with HMG-CoA 
reductase being the rate-limiting enzyme. Suppression of this enzyme may occur 
if cholesterol synthesis is excessive. Involved in these processes is a family of 
transcription-regulating proteins called sterol regulatory element-binding 
proteins. Intracellular cholesterol accumulation also reduces the number of 
hepatic LDL receptors, and therefore LDL entry into cells declines and the 
plasma concentration rises. However, if the dietary intake of cholesterol is 
excessive, intracellular accumulation can occur. About 30–60 per cent of the 
dietary intake of cholesterol (of 1–2 mmol) is absorbed, this amount being 
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increased if the diet is rich in saturated fat. High saturated fat intake can also 
suppress LDL receptor activity and is a driver of cholesterol metabolism than 
dietary cholesterol. The richest dietary sources of cholesterol are egg yolks, dairy 
products and red meat. 
Familial hyperlipidemias: 
Table: Fredrickson’s classification of hyperlipidaemias 
 
Type Electrophoretic Increased lipoprotein 
I Increased chylomicrons Chylomicrons 
IIa Increased b-lipoproteins LDL 
IIb Increased b and pre-b-
lipoproteins 
LDL and VLDL 
III Broad b-lipoproteins IDL 
IV Increased pre-b-
lipoproteins 
VLDL 
V Increased chylomicrons and 
pre-b- lipoproteins 
Chylomicrons and VLDL 
IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, 
very low-density lipoprotein. 
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IV. MATERIALS AND METHODS 
 
SOURCE OF THE STUDY 
        Primary data collected by me from the cases of cirrhosis of liver from all 
causes getting admitted in medical wards of Coimbatore medical college 
hospital. 
STUDY DESIGN 
        Cross-sectional study 
STUDY PERIOD 
July 2017 to June 2018. 
METHODOLOGY 
This is cross sectional study on lipid profile as an indicator of severity in 
cirrhosis of liver in 120 patients admitted to the medical ward in Coimbatore 
medical college of hospital with cirrhosis of liver due to various causes 
diagnosed clinically, biochemically and radiologically. Fasting serum lipid 
profile is measured in all patients diagnosed with cirrhosis. Total serum 
cholesterol, triglycerides and HDL were measured by direct method and serum 
LDL, VLDL has been calculated by using Friedewald formula. 
LDL cholesterol = Total cholesterol – {HDL cholesterol-TGL/5} 
VLDL = Sr. Triglycerides / 5 
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INCLUSION CRITERIA 
  Patients age more than 18 years with cirrhosis 
EXCLUSION CRITERIA 
 Diabetes mellitus / hypertension 
 Cerebrovascular disease  
 Patients on lipid lowering drugs 
 Pancreatitis 
 Chronic kidney disease 
 Hypo/hyperthyroidism 
The primary collected by me was analyzed using SPSS 16.0 version 
software. Multiple variables between variable groups of single population done 
by using chi square test. Quantitative data between two or more groups were 
analyzed using ANOVA test. 
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V. RESULTS 
 
TABLE 1: AGE DISTRIBUTION 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
20-29 6 5 
30-39 19 15.8 
40-49 43 35.8 
50-59 40 33.3 
 
     In this study, mean age of the participants were 47.3 with the standard 
deviation of 9.1 which ranges from 20-65 years. Most participants are happened 
to be in the range of 40-60 years of age.  
 
 
 
6  % 
19 % 
43 % 
40 % 
12% 
Age Distribution of the study participants with 
Cirrhosis 
20-29 
30-39 
40-49 
50-59 
>59 
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TABLE 2: SEX DISTRIBUTAION 
SEX NO OF PATIENTS PERCENTAGE 
MALE 76 63% 
FEMALE 44 37% 
 
 
In this study males (76) which is 63% and females of (44) 37% were studied, 
TABLE 3: ASCITES 
Ascites NO OF PATIENTS PERCENTAGE 
Yes 98 82% 
No 22 18% 
 
 
76 (63%) 
44 (37%) 
Gender of study participants 
with Cirrhosis 
Male 
Female 
98 (82%) 
22 (18%) 
Presence of Ascites among study 
partcipants with Cirrhosis 
Yes 
No 
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TABLE 4: UPPER GASTROINTESTINAL BLEEDING 
UGI Bleeding NO OF PATIENTS PERCENTAGE 
Yes 29 24% 
No 91 76% 
 
 
TABLE 5: ENCEPHALOPATHY 
Encephalopathy NO OF PATIENTS PERCENTAGE 
Yes 23 19% 
No 97 81% 
 
 
0% 
29 (24%) 
91 (76%) 
Presence of Upper Gastrointestinal Bleeding among study 
partcipants with Cirrhosis 
Yes 
No 
0% 
23 (19%) 
97 (81%) 
Presence of encephalopathy among study 
partcipants with Cirrhosis 
Yes 
No 
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TABLE 6: SBP 
SBP NO OF PATIENTS PERCENTAGE 
Yes 23 19% 
No 97 81% 
 
 
TABLE 7: HEPATORENAL SYNDROME 
Hepatorenal Syndrome NO OF PATIENTS PERCENTAGE 
Yes 13 11% 
No 107 89% 
 
 
 
0% 
23 (19%) 
97 (81%) 
Presence of SBP among study 
partcipants with Cirrhosis 
Yes 
No 
0% 
13 
(11%) 
107 (89%) 
Presence of Hepatorenal Syndrome among study 
partcipants with Cirrhosis 
Yes 
No 
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TABLE 8 : HEPATOPULMONARY SYNDROME 
Hepatopulmonary Syndrome NO OF PATIENTS PERCENTAGE 
Yes 3 2% 
No 117 98% 
 
TABLE 9 : CHILD PUGH SCORE 
Child Pugh Score NO OF PATIENTS PERCENTAGE 
A 44 36.7 
B 50 41.7 
C 26 21.7 
 
In my study among total of 120 patients , 44 patients were under the child pugh 
score category A (36.7%), 50 comes under category B (41.7%), 26 comes under 
category C(21.7%).  
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Child Pugh Score 
Child Pugh Score distribution among 
participants with Cirrhosis 
A 
B 
C 
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TABLE 10 : MELD SCORE 
MELD Score NO OF PATIENTS PERCENTAGE 
1 to 10 4 3.3 
11 to 18 16 13.3 
19 to 24 37 30.8 
>24 63 52.5 
 
In this study mean MELD score was 26.1 with the SD of 8.4. It ranges 
from 10-50 
 
 
TABLE 11:  ETIOLOGY OF CIRRHOSIS 
Etiology NO OF PATIENTS PERCENTAGE 
Alcoholic 84 75.0 
Hepatitis B 8 7.1 
NASH 6 5.4 
Cryptogenic 3 2.7 
Heart Failure 3 2.7 
EHPVO 2 1.8 
HCC 2 1.8 
Autoimmune hepatitis 1 0.9 
Wilson disease 1 0.9 
Budd Chiari Syndrome 1 0.9 
Primary biliary Cirrhosis 1 0.9 
 
[VALUE] 
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[VALUE] 
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TABLE 12: TREATMENT OUTCOME 
Treatment Outcome NO OF PATIENTS PERCENTAGE 
Live 115 95.8 
Dead 5 4.2 
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GE]) 
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Treatment Outcome among study 
patients with Cirrhosis 
Live 
Dead 
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TABLE 13: LIPID PROFILE ACCORDING TO CHILD PUGH SCORE 
CLASSIFICTION 
Lipid Profile characteristics Child Pugh Score 
A  
(n-44) 
B 
(n-50) 
C  
(n-26) 
Cholesterol Mean±SD 176.9 (12.0) 148.6 (11.8) 121.4 (9.5) 
Range 152-210 130-178 102-134 
95% Confidence 
interval 
173.2-180.5 145.3-152.0 117.6-125.3 
P value (Anova) <0.001 
Triglyceride Mean±SD 152.1 (9.0) 130.1 (8.6) 92.7 (9.9) 
Range 125-174 110-145 74-112 
95% Confidence 
interval 
149.3-154.8 127.7-132.6 88.7-96.7 
P value (Anova) <0.001 
LDL Mean±SD 101.5 (12.4) 86.6 (10.9) 74.3 (10.3) 
Range 77-140.6 69.6-116 57.6-94.4 
95% Confidence 
interval 
97.7-105.3 83.5-89.7 70.1-78.5 
P value (Anova) <0.001 
VLDL Mean±SD 30.4 (1.8) 26.0 (1.7) 18.5 (2.0) 
Range 25-34.8 22-29 14.8-22.4 
95% Confidence 
interval 
29.9-31.0 25.5-26.5 17.7-19.3 
P value (Anova) <0.001 
HDL Mean±SD 45.0 (5.2) 36.0 (4.7) 28.6 (4.3) 
Range 34-55 28-45 22-37 
95% Confidence 
interval 
43.4-46.5 34.7-37.3 26.8-30.3 
P value (Anova) <0.001 
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In my study depending on the child pugh score lipid profile changes has 
been depicted. Cholesterol level found to be lowest in child pugh category C 
when compared to child pugh score B then to A, with the mean value of 
176.9+12 in group A, 148.6+11.8 in group B and 121.4+9.5 in group3+ C. it is 
found statistically significant with the P value <0.001. 
The triglyceride values were found statistically significant with mean 
value of 152+9 in group A, 130+8.6 in group B and 92.7+9.9 in group C with P 
value of <0.001. 
The serum LDL levels were calculated, mean value of 101.5+12.4 in 
group A, 86.6+10.9 in group B and 74+10.3 in group C, found statistically 
significant. 
The serum VLDL values were calculated mean values are 30.4+1.8 
(group A), 26+1.7 (group B) and 18.2+2.0 (group C), which are statistically 
significant. 
The serum HDL values are measured with mean values of 45+5.2 in 
group A, 36+4.7 in group B and 28.6+4.3 in group C which are statistically 
significant with P value of <0.001. 
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TABLE 14; LIPID PROFILE DEPENDS ON MELD SCORE 
Lipid Profile characteristics MELD Score 
≤10 
(n-4) 
11-18 
(n-16) 
19-24 
(n-37) 
>24 
(n-63) 
Cholesterol Mean±SD 165.0 
(18.7) 
170.1 
(18.5) 
164.8 
(18.0) 
141.1 
(22.0) 
Range 143-188 130-188 134-210 102-192 
95% Confidence 
interval 
135.2-
194.8 
160.3-
180.0 
158.8-
170.8 
135.6-
146.7 
P value (Anova) <0.001  
Triglyceride Mean±SD 143.3 
(16.8) 
143.8(15.5) 143.6 
(13.7) 
117.8 
(24.1) 
Range 123-158 112-167 121-174 74-162 
95% Confidence 
interval 
116.6-
169.9 
135.5-
152.1 
139.0-
148.2 
111.7-
123.8 
P value (Anova) <0.001  
LDL Mean±SD 94.9 (9.6) 99.3 (12.5) 94.5 
(14.9) 
83.6 
(14.2) 
Range 85.4-
107.4 
75.6-116 69.6-
140.6 
57.6-
114.2 
95% Confidence 
interval 
79.6-
110.1 
92.6-106.0 89.5-99.4 80.0-87.1 
P value (Anova) <0.001  
VLDL Mean±SD 28.7 (3.4) 28.8 (3.1) 28.7 
(2.7) 
23.6 (4.8) 
Range 24.6-31.6 22.4-33.4 24.2-34.8 14.8-32.4 
95% Confidence 
interval 
23.3-34.0 27.1-30.4 27.8-29.6 22.3-24.8 
P value (Anova) <0.001  
HDL Mean±SD 41.5 (6.6) 42.1 (7.4) 41.6 
(6.6) 
34.0 (7.0) 
Range 33-49 28-54 28-55 22-54 
95% Confidence 
interval 
31.0-52.0 38.1-46.0 39.4-43.8 32.2-35.8 
P value (Anova) <0.001  
 
The mean values of serum total cholesterol, LDL, VLDL, HDL, 
triglycerides were found progressively decreased as the MELD score increases. 
This was found statistically significant with the P value of <0.001. 
67 
 
               Cholesterol level            Triglyceride level 
  
 
 
               LDL level                VLDL level 
 
   
 
HDL Level        Cholesterol level 
      
68 
 
            Triglyceride level      LDL level 
 
  
  VLDL level                                             HDL Level 
 
     
 
 
 
 
 
 
 
69 
 
TABLE 15: GENDER WISE DISTRIBUTION OF LIPID PROFILE 
CHARACTERISTICS 
Lipid Profile characteristics 
Gender  
Male 
(n-76) 
Female 
(n-44) 
P value* 
Cholesterol Mean±SD 152.9 (23.0) 153.4 (26.3) 0.91 
Triglyceride Mean±SD 130.6 (23.1) 129.1 (25.1) 0.73 
LDL Mean±SD 89.4 (14.3) 89.4 (17.1) 0.99 
VLDL Mean±SD 26.1 (4.6) 25.8 (5.0) 0.73 
HDL Mean±SD 37.4 (7.9) 38.2 (7.9) 0.59 
*independent t test 
TABLE 16: AGEWISE DISTRIBUTION OF LIPID PROFILE 
CHARACTERISTICS 
Lipid Profile 
characteristics 
Age group  
20-29 
(n-6) 
30-39 
(n-19) 
40-49 
(n-43) 
50-59 
(n-40) 
>59 
(n-12) 
P 
value* 
Cholesterol Mean±SD 161.0 
(17.9) 
150.4 
(21.6) 
151.5 
(23.3) 
156.1 
(27.1) 
149.0 
(20.2) 
0.73 
Triglyceride Mean±SD 139.4 
(24.7) 
130.6 
(22.6) 
127.4 
(23.4) 
132.1 
(24.6) 
127.3 
(25.8) 
0.76 
LDL Mean±SD 95.1 
(10.1) 
87.7 
(12.7) 
89.1 
(14.5) 
90.1 
(18.5) 
87.8 
(13.3) 
0.86 
VLDL Mean±SD 27.9 
(4.9) 
26.1 
(4.5) 
25.5 
(4.7) 
26.4 
(4.9) 
25.5 
(5.2) 
0.76 
HDL Mean±SD 38.0 
(7.0) 
36.6 
(8.3) 
36.9 
(9.0) 
39.5 
(6.7) 
35.8 
(6.5) 
0.47 
*ANOVA 
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TABLE 17: PRESENCE OF ASCITES AND DISTRIBUTION OF LIPID 
PROFILE CHARACTERISTICS 
Lipid Profile characteristics 
Ascites  
Yes 
(n-98) 
No 
(n-22) 
P value* 
Cholesterol Mean±SD 150.3 (22.6) 165.4 (25.4) 0.007 
Triglyceride Mean±SD 129.1 (24.0) 134.2 (22.7) 0.365 
LDL Mean±SD 87.5 (14.9) 97.7 (14.8) 0.005 
VLDL Mean±SD 25.8 (4.8) 26.8 (4.5) 0.365 
HDL Mean±SD 36.9 (7.6) 40.9 (8.2) 0.032 
*independent t test 
TABLE 18: PRESENCE OF UGI BLEEDING AND DISTRIBUTION OF 
LIPID PROFILE CHARACTERISTICS 
Lipid Profile characteristics 
UGI Bleeding  
Yes 
(n-29) 
No 
(n-91) 
P value* 
Cholesterol Mean±SD 154.7 (26.3) 152.5 (23.0) 0.671 
Triglyceride Mean±SD 130.9 (24.3) 129.8 (23.7) 0.821 
LDL Mean±SD 89.8 (15.4) 89.3 (15.4) 0.856 
VLDL Mean±SD 26.2 (4.8) 25.9 (4.7) 0.821 
HDL Mean±SD 38.7 (7.8) 37.4 (7.9) 0.426 
*independent t test 
TABLE 19: PRESENCE OF SBP AND DISTRIBUTION OF LIPID 
PROFILE CHARACTERISTICS 
Lipid Profile characteristics 
SBP  
Yes 
(n-23) 
No 
(n-97) 
P value* 
Cholesterol Mean±SD 142.5 (21.0) 155.6 (23.8) 0.017 
Triglyceride Mean±SD 124.0 (25.3) 131.5 (23.3) 0.178 
LDL Mean±SD 83.0 (11.7) 90.9 (15.7) 0.025 
VLDL Mean±SD 24.8 (5.1) 26.3 (4.7) 0.178 
HDL Mean±SD 34.7 (8.4) 38.4 (7.6) 0.045 
*independent t test 
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TABLE 20: SEX WISE DISTRIBUTION OF CHILD PUGH SCORE 
Sex 
Child Pugh Score  
A 
(n-44) 
B 
(n-50) 
C 
(n-26) 
P value* 
Male 30 (68.2) 29 (58.0) 17 (65.4) 0.58 
Female  14 (31.8) 21 (42.0) 9 (34.6) 
    *Chi square test 
 
Figure: Sexwise distribution of Child Pugh Score 
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TABLE 21: CHILD PUGH SCORE DISTRIBUTION RELATED TO 
PRESENCE OF ASCITES 
Presence of ascites 
Child Pugh Score  
A 
(n-44) 
B 
(n-50) 
C 
(n-26) 
P value* 
Yes 31 (70.5) 44 (88.0) 98 (81.7) 0.065 
No 13 (29.5) 6 (12.0) 3 (11.5) 
      *Fischer’s Exact test 
 
Figure: Child Pugh Score distribution related to presence of ascites 
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TABLE 22: CHILD PUGH SCORE DISTRIBUTION RELATED TO 
PRESENCE OF UGI BLEEDING 
Presence of UGI 
Bleeding 
Child Pugh Score  
A 
(n-44) 
B 
(n-50) 
C 
(n-26) 
P value* 
Yes 15 (34.1) 7 (14.0) 7 (26.9) 0.071 
No 29 (65.9) 43 (86.0) 19 (73.1) 
        *Chi square test 
 
Figure: Child Pugh Score distribution related to presence of UGI Bleeding 
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TABLE 23: CHILD PUGH SCORE DISTRIBUTION RELATED TO 
PRESENCE OF ENCEPHALOPATHY 
Presence of 
encephalopathy 
Child Pugh Score  
A 
(n-44) 
B 
(n-50) 
C 
(n-26) 
P value* 
Yes 0 (0) 4 (8.0) 19 (73.1) <0.001 
No 44 (100) 46 (92.0) 7 (26.9) 
*Fischer’s exact test 
 
Figure: Child Pugh Score distribution related to presence of 
encephalopathy 
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TABLE 24: CHILD PUGH SCORE DISTRIBUTION RELATED TO 
PRESENCE OF SBP 
Presence of SBP 
Child Pugh Score  
A 
(n-44) 
B 
(n-50) 
C 
(n-26) 
P value* 
Yes 6 (13.6) 9 (18.0) 8 (30.8) <0.21 
No 38 (86.4) 41 (82.0) 18 (69.2) 
       *Fischer’s exact test 
Figure: Child Pugh Score distribution related to presence of SBP 
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TABLE 25: CHILD PUGH SCORE DISTRIBUTION RELATED TO 
PRESENCE OF HEPATOPULMONARY SYNDROME 
Presence of 
Hepatopulmonary 
syndrome 
Child Pugh Score  
A 
(n-44) 
B 
(n-50) 
C 
(n-26) 
P value* 
Yes 0 (0) 5 (10.0) 8 (30.8) <0.001 
No 44 (100) 45 (90.0) 18 (69.2) 
*Fischer’s exact test 
 
 
Figure: Child Pugh Score distribution related to presence of 
Hepatopulmonary syndrome
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TABLE 26: CHILD PUGH SCORE DISTRIBUTION RELATED TO 
PRESENCE OF HEPATORENAL SYNDROME 
Presence of Hepatorenal 
syndrome 
Child Pugh Score  
A 
(n-44) 
B 
(n-50) 
C 
(n-26) 
P value* 
Yes 0 (0) 0 (0) 3 (11.5) 0.009 
No 44 (100) 50 (100) 23 (88.5) 
   *Fischer’s exact test 
Figure: Child Pugh Score distribution related to presence of Hepatorenal 
syndrome 
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TABLE 27: SEX WISE DISTRIBUTION OF MELD SCORE 
Sex 
MELD score  
≤10 
(n-4) 
11-18 
(n-16) 
19-24 
(n-37) 
>24 
(63) 
P 
value* 
Male 2 (50.0) 10 (62.5) 22 (59.5) 42 (66.7) 
0.81 
Female 2 (50.0) 6 (37.5) 15 (40.5) 21 (33.3) 
    *Fishcers’ Exact test 
 
Figure: Sexwise distribution of MELD Score 
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TABLE 28 : MELD SCORE DISTRIBUTION WITH PRESENCE OF UGI 
BLEEDING 
Presence of 
UGI 
Bleeding 
MELD score  
≤10 
(n-4) 
11-18 
(n-16) 
19-24 
(n-37) 
>24 
(63) 
P 
value* 
Yes 3 (75.0) 2 (12.5) 9 (24.3) 15 (23.8) 
0.106 
No 1 (25.0) 14 (87.5) 28 (75.7) 48 (76.2) 
   *Fishcers’ Exact test 
Figure: MELD Score distribution with presence of UGI Bleeding 
 
  
80 
 
TABLE 29: MELD SCORE DISTRIBUTION WITH PRESENCE OF 
ENCEPHALOPATHY 
Presence of 
encephalopathy 
MELD score  
≤10 
(n-4) 
11-18 
(n-16) 
19-24 
(n-37) 
>24 
(63) 
P 
value* 
Yes 0 (0) 0 (0) 1 (2.7) 22 (34.9) 
<0.001 
No 4 (100) 16 (100) 36 (97.3) 41 (65.1) 
*Fishcers’ Exact test 
Figure: MELD Score distribution with presence of encephalopathy 
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TABLE 30: MELD SCORE DISTRIBUTION WITH PRESENCE OF 
HEPATOPULMONARY SYNDROME 
Presence of 
Hepatopulmonary 
syndrome 
MELD score  
≤10 
(n-4) 
11-18 
(n-16) 
19-24 
(n-37) 
>24 
(63) 
P 
value* 
Yes 0 (0) 0 (0) 4 (10.8) 9 (14.3) 
0.457 
No 4 (100) 16 (100) 33 (89.2) 54 (85.7) 
*Fishcers’ Exact test 
 
Figure: MELD Score distribution with presence of Hepatopulmonary 
syndrome 
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TABLE 31: MELD SCORE DISTRIBUTION WITH PRESENCE OF 
HEPATORENAL SYNDROME 
Presence of 
Hepatorenal 
syndrome 
MELD score  
≤10 
(n-4) 
11-18 
(n-16) 
19-24 
(n-37) 
>24 
(63) 
P 
value* 
Yes 0 (0) 0 (0) 0 (0) 3 (4.8) 
0.593 
No 4 (100) 16 (100) 37 (100) 60 (95.2) 
    *Fishcers’ Exact test 
Figure: MELD Score distribution with presence of Hepatorenal syndrome 
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DISCUSSION 
 
Dyslipidemia is frequent founding in cases of diabetes mellitus, 
cardiovascular disease, cerebrovascular disease, etc. Though they are studies 
predicting the lipid profile changes in cirrhosis patients, they found to be less in 
number in our Tamilnadu. Since the case load in our Coimbatore medical college 
hospital is surplus, we had interest in depicting the lipid profile changes in 
cirrhosis and considering this as a newly added prognostic indicator in assessing 
the severity of cirrhosis. 
We have selected 120 cases (males=76; females=44) of cirrhosis 
diagnosed using clinical features like jaundice, ascites, upper gastrointestinal 
bleed, hepatic encephalopathy, hepatorenal syndrome, etc confirmed by 
biochemical tests i.e complete blood count, liver function tests, coagulation 
profile and tests towards the etiology of cirrhosis like viral markers, serum 
ceruloplasmin, ANA profile, serum iron studies. Further those patients were 
imaged by ultrasonogram of abdomen and proceeded with 
oesophagogastroduodeno scopy for varices. 
Results were consistent with previous studies. In our study, we found that 
parameters like serum total cholesterol, LDL, VLDL, HDL, triglycerides were 
significantly lower as the stage of severity of cirrhosis advances. Fazl subhan, 
Imran khan et al conducted similar study in which they have concluded that 
serum cholesterol, LDL, HDL were significantly reduced in patients with 
cirrhosis in comparison with control, where TGL levels were statistically not 
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significant. Serum cholesterol and other parameter significantly reduced as the 
synthetic function of liver is affected enormously in cirrhosis because of fibrosis 
and nodule formation.  
In our study depending on the Child Pugh Turcott score lipid profile 
changes has been depicted. Cholesterol level found to be lowest in Child Pugh 
Turcott category C when compared to Child Pugh Turcott score B then to A, 
with the mean value of 176.9+12 in group A, 148.6+11.8 in group B and 
121.4+9.5 in group3+ C. It is found statistically significant with the P value 
<0.001.  
The triglyceride values were found statistically significant with mean 
value of 152+9 in group A, 130+8.6 in group B and 92.7+9.9 in group C with P 
value of <0.001. 
The serum LDL levels were calculated, mean value of 101.5+12.4 in 
group A, 86.6+10.9 in group B and 74+10.3 in group C, found statistically 
significant. 
The serum VLDL values were calculated mean values are 30.4+1.8 
(group A), 26+1.7 (group B) and 18.2+2.0 (group C), which are statistically 
significant. The serum HDL values are measured with mean values of 45+5.2 in 
group A, 36+4.7 in group B and 28.6+4.3 in group C which are statistically 
significant with P value of <0.001. 
Our study showed that, cholesterol level in more in Child grade A when 
compared to Child grade B in turn with grade C. Suman, Ramesh kumar, 
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Prabahar et al conducted similar study in Hyderabad showed serum cholesterol 
and LDL levels had high area under curve which statistically significant 
associated with cirrhosis severity. In that study they compared the results with 
healthy individuals.  
In Suman et al study the most common cause of cirrhosis is of viral 
etiology. They also compared alcoholic cirrhosis with non-alcoholic cirrhosis 
patients. Total cholesterol mean value of 137mg/dl in Child C, LDL level was 
<75mg/dl. 
One more study conducted in Kerala by Hasik, Mohammed et al 
concluded that mean values of serum total cholesterol, LDL, HDL, Triglycerides 
were significantly lower in Child Pugh grade C in comparison with other grades.  
The decreased levels of LDL, HDL might be attributed to reduced 
synthesis of apolipoproteins A and B. Since the apo B is involved in synthesis of 
VLDL, the reduced level of triglycerides is explained in cirrhosis. This can be 
due to insulin resistance found in liver cirrhosis. Insulin signaling mechanism in 
cirrhosis is found critical for lipogenesis regulated by PI3K and AKT2 signaling 
pathways. Among the various transcription factors, sterol regulatory element 
binding protein-1c (SREBP-1c) has stimulatory effect on the genes involving in 
lipogenesis.  
Insulin activates the lipogenesis pathway in liver by SREBP-1c signaling 
pathway. Because of increased number of insulin receptors in patients with 
cirrhosis changes in lipid profile are encountered. AKT2 which is involved in 
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hepatic lipid accumulation explains one of the etiological factors of fatty liver. 
The pathophysiology of fatty liver first initiated by lipid accumulation followed 
by inflammation and oxidative stress. As the disease progresses from fibrosis to 
cirrhosis, the inflammatory process and oxidative stress are responsible for 
augmentation of insulin receptors. 
The international monthly journal of hepatology December 2010 showed 
a significant decrease in levels of serum total cholesterol, LDL, HDL and 
triglycerides in cirrhosis as the severity increases.  
The journal of Arab society for medical research 2012 depicted that the 
changes of lipid profile in cirrhosis patients irrespective of the incidence of 
hepatocellular carcinoma. The TGL levels and LDL levels are inversely related 
to the severity of cirrhosis and the changes are also correlated with 
hepatocellular carcinoma. 
Our study lacks correlation of lipid profile abnormalities with 
complications of cirrhosis. Though the results are depicted significant with 
hepatorenal syndrome and hepatic encephalopathy. 
Lipid profile abnormalities have well documented negative correlation 
with severity of cirrhosis. This study ensures that lipid profile abnormalities in 
cirrhosis as the synthetic function impaired in those patients. The correlation 
between complications of cirrhosis and lipid profile changes need further studies 
to be clarified. In near future as like Child Pugh Turcott score and MELD score 
lipid profile parameters can be included as an indicator of severity of cirrhosis.  
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Currently, cirrhosis is considered a dynamic disease able to progress and 
regress.in this new way of thinking the spectrum of changes characterizing 
chronic liver disease, early diagnosis and intervention is an important step to 
stop progression to decompensation and leads to high mortality. Step to arrest 
the progression to decompensation is an ominous step in the natural course of the 
disease. Transient elastography (Fibroscan) is an accurate non-invasive 
identification of patients who is having fibrosis progressing to cirrhosis by using 
score. Prevention or postponing the decompensation mainly by reducing the 
portal pressure by using long standing non selective beta blockers. Once the 
decompensation sets in, ultimate aim is to avoid further decompensation in the 
form of complications and reduce the mortality.  
 TIPS is effective in decreasing the risk of variceal bleeding and which 
improves the mortality in patients with recurrent ascites and refractory ascites. In 
few studies statins are associated with reduced incidence of HCC and hepatic 
portal venous pressure gradient. Role of Anticoagulants in cirrhosis is reserved 
for patients with portal vein thrombosis awaiting liver transplantation. Some 
clinical trails show not only reduced risk of portal vein thrombosis but also 
delayed decompensation and improved survival. Rifaximin is a potential 
alternative in prevention od SBP since it has lower bacterial resistance 
documented.  
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                                                     SUMMARY 
 Cirrhosis is one of the commonest diseases worldwide. 
 Fourteenth common cause of death worldwide, tenth most common cause 
of death in India as per world health organization. It may affect one in 
five Indians. 
 Hepatocellular carcinoma is the second most common cause of death due 
to malignancy in world. 
 There are various scoring system available to assess the severity of 
cirrhosis like Child Pugh Turcotte score includes serum bilirubin, ascites, 
encephalopathy, serum albumin and PT-INR. Model for end stage liver 
diseases (MELD) score also used for prioritizing patients for liver 
transplantation. 
 Lipid metabolism is solely depend on liver. Hence, in cirrhosis the levels 
of lipid profile parameters like serum total cholesterol, LDL,VLDL, TGL, 
HDL are reduced with increasing severity of cirrhosis. 
 Considering lipid profile abnormalities in chronic liver disease is 
paramount importance to assess the severity since the changes are 
correlating statistically significant with previously existing severity 
assessment score like Child Pugh Turcotte score and with the MELD 
score. 
 Unlike other studies, in our study all the parameters of lipid profile 
namely, serum total cholesterol, serum HDL, triglycerides (measured by 
direct method), serum VLDL, LDL (calculated by formula) have been 
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found to be reduced with as the severity of cirrhosis increases. Lipid 
lowering drugs can be used in lower doses in cirrhotics. 
 In a patient presenting with anasarca, evaluation of lipid profile can 
differentiate nephrotic patient from cirrhotics.  
 In patients with cirrhosis and portal hypertension, the complications of 
cirrhosis has not found to be correlated with lipid profile abnormalities. 
  However, hepatic encephalopathy and hepatorenal syndrome which were 
found to be significantly reduced in than patients without those 
complications.  
 In patients with ascites total cholesterol and LDL are correlating well with 
increasing severity. 
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CONCLUSION 
Lipid profile changes are common findings in patients with cirrhosis. In 
this study it was found that there is significant reduction in levels of lipid profile 
parameters like serum total cholesterol, LDL, VLDL, TGL, HDL in patients with 
cirrhosis as the severity increases. Presence of low lipid levels in cirrhosis 
patients presenting with altered sensorium and renal failure can aid in diagnosis 
of complications like hepatorenal syndrome and hepatic encephalopathy. Further 
formulation of scoring system in association with preexisting score system may 
provide better assessment of patients’ prognosis in view of morbidity and 
mortality. Also it is cast effective method. We recommend it is necessary to 
assess fasting lipid profile in all patients with cirrhosis and prognosticate the 
disease progression. 
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ANNEXURE - 1 
PROFORMA 
 
Name:                                    IP No : 
Age/Sex:                                 DOA:                                 D.O.D : 
Religion:                                  Hospital : 
Address:                                 Occupation : 
I. PRESENTING COMPLAINTS: 
1. Distention of abdomen                      8. Dyspeptic symptoms 
2. Swelling of lower limbs                    9. Loss of appetite /weight 
3. Pain abdomen                                 10. Haemetamesis 
4. Mass per abdomen                             11. Bleeding per rectum 
5. Fever                                                   12. Sleep disturbance 
6. Yellowish discoloration of eyes 
7. Altered sensorium 
II. PAST HISTORY 
a. Similar ailments like presenting symptoms 
b. Previous hospitalization for similar complaints 
c. History of Jaundice in the past 
d. Blood transfusion 
e. Intake of Hepatotoxic drugs 
f. History of Immunization 
g. Past history of any abdominal surgeries 
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h. Other illness 
III. PERSONAL HISTORY 
a. Diet : Veg./mixed 
b. Sleep : Disturbed/undisturbed 
c. Alcohol consumption : Duration 
d. Bowel and bladder habits 
IV. GENERAL PHYSICAL EXAMINATION 
Built :                      Nourishment : 
Scalp hair :              Weight : 
Skin :                       Height : 
Conjunctiva :  Sclera : 
Oral cavity : 
 
Neck :  Lymph node enlargement  :  Yes / No 
Thyroid enlargement  :  Yes / No 
Parotid enlargement  :  Yes / No 
 
Upper Limbs :  
 Flapping tremors 
Dupytrens contracture 
Palmar erythema 
Spider Naevi 
Oedema  :          Pitting / non pitting : 
Jugular venous pulse  : 
Foetar hepaticus  : 
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Anaemia  : 
Icterus  : 
Cyanosis  : 
Clubbing  : 
Lymph nodes  : 
Gynaecomastia  : 
Vital signs                                                 
Pulse/min  :  Blood pressure in mm Hg  :                            
Temperature  :                      Respiratory rate   : 
 
V. SYSTEMIC EXAMINATION: 
 I. Abdominal Examination: 
a. Inspection 
Shape  :  Scaphoid/uniform distention 
Umbilicus  :  Transverse/vertical eversion 
Skin over the abdomen  :  Dry/tense/glistening 
Dilatation of abdominal wall veins :  Around umbilicus/Flanks 
Movements of all quadrants of abdomen :   Normal/Restricted 
Visible persistalisis  : 
Scars and sinuses  : 
Hernial orifices : 
External genetalia : 
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b. Palpation 
Edema of the abdominal wall 
Muscle guarding/rigidity 
Tenderness 
Abdominal girth at umbilical level 
Liver  :  Palpable /Not 
Size  :  Cms below right costal margin in mid clavicular line 
Consistency  :  Soft/firm/hard 
Surface  :  Smooth/Nodu1ar/Irregu1ar 
Border  :  Sharp/Blunt 
Tenderness  :  Present/Absent 
Spleen  :  Palpable : Yes/No 
Size  :  Cms below left costal margin in mid clavicular Line 
Consistency  :  Soft/firm/hard 
Tenderness  :  Present/Absent 
Any other palpable mass : 
Measurements of abdomen: 
Abdominal girth at umbilicus : 
Distance between umbilicus and pubic symphysis : 
Distance between umbilicus and xiphisternum : 
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c. Percussion 
Fluid thrill  :  Present/Absent 
Shifting dullness  :  Present/Absent 
Liver dullness  :  cms below right costal margin mid clavicular line 
Splenic dullness  :  Present/Absent 
d. Ausculitatiion 
Over Liver  :  Rub/Bruit 
Over spleen  :  Rub 
Bowel sounds  : 
 
2. Cardio Vascular system examination 
3. Respiratory system examination 
4. Central nervous system examination 
 
IX. INVESTIGATIONS 
1. Routine Haematological examination 
Hb gm%  : 
Total Count  : 
Differential count  : 
2. Urine analysis   
Sugar  :     Albumin         : 
 Microscopy  :    Bile salts/Bile pigments : 
Urobilinogen  : 
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3. Random blood sugar in mg/dl : 
4. Blood urea in mg/dl  : 
5. Serum creatinine in mg/dl  : 
6. Liver function tests  : 
Serum total Billirubin  : 
Serum total proteins : 
Serum Albumin  : 
Serum Globulin  : 
Albumin/Globulin ratio  : 
S.G.O.T  : 
S.G.P.T  : 
Serum Alkaline Phosphotase  : 
7. Lipid profile  : 
Tota cholesterol  : 
HDL  : 
LDL  : 
Triglyceride  : 
VLDL  : 
8.PT &INR  : 
8.ECG  : 
9.Ultrasound abdomen  : 
DIAGNOSIS 
TREATMENT  : 
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ANNEXURE - 2 
CONSENT FORM 
 
Yourself Mr./Mrs./Ms………………………………..  are being asked to be a 
participant in the research study titled A STUDY ON LIPID PROFILE AS AN 
INDICATOR OF SEVERITY IN CIRRHOSIS OF LIVER” in CMC 
Hospital, Coimbatore, conducted by Dr. Yamuna J,  Post Graduate Student, 
Department of General Medicine, Coimbatore Medical College. You are eligible 
after looking into the inclusion criteria. You can ask any question you may have 
before agreeing to participate. 
 
Research Being Done 
A study on lipid profile abnormalities in cirrhosis patients. 
 
Purpose of Research 
  To investigate the lipid profile changes in patients with cirrhosis  
Decline from Participation 
You have the option to decline from participation in the study existing 
protocol for your condition. 
Privacy and Confidentiality 
Privacy of individuals will be respected and any information about you or 
provided by you during the study will be kept strictly confidential. 
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Authorization to publish Results   
Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified.               
 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the consent 
or it has been read to me. The study has been fully explained to me, and I may 
ask questions at any time. 
 
-------------------------------                           -------------------------------   
Signature /Left thumb impression                       Date 
(volunteer)   
 
--------------------------------                          -------------------------------- 
Signature of witness                                               Date 
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 ஒப்புதல் படிவம் 
பெயர் : 
வயது : 
ொலினம் : 
முகவரி: 
 
ககாவவ அரசு மருத்துவக்கல்லூரி மருத்துவமவனயில் 
மருத்துவர் -தவலவமயில் நவைபெறும் இந்த ஆய்வில் முழு 
சம்மதத்துைன் கலந்துபகாள்ள சம்மதிக்கிகேன். இந்த 
ஆய்வில் என்வன ெற்ேி விவரங்கவள ொதுகாப்புைன் இந்த 
ஆய்வில்  பவளியிை ஆட்கசெவை இல்வல என்று 
பதரிவித்துக் பகாள்கிகேன். எந்த கநரத்திலும் ஆய்வில் 
இருந்து எந்த கநரத்திலும் விலக்கிக்பகாள்ளும்  உரிவம 
உண்டு என்று அேிகவன். 
 
இைம் : 
கததி: 
 
                                                                                               வகபகயாப்ெம்  /
கரவக 
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ANNEXURE - 3 
KEY TO MASTER CHART 
SERIAL NUMBER 
NAME 
AGE 
SEX 
ASCITES – YES/NO 
UGI BLEED- YES/NO 
HEPATIC ENCEPHALOPATHY- YES/NO 
SBP – YES/NO 
HEPATORENAL SYNDROME- YES/NO 
HEPATOPULMONARY SYNDROME- YES/NO 
ETIOLOGY 
CHILD PUGH SCORE – A (), B (), C () 
MELD SCORE 
CHOLESTEROL 
TRIGLYCERIDES 
LDL 
VLDL 
HDL 
OUTCOME 
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ANNEXURE - 4 
Master Chart 
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1 JEEVA 54 M YES NO NO YES NO NO NASH A 14 172 152 94.6 30.4 47 
 
2 FRANCIS 43 M YES NO NO NO YES NO ALCOHOLIC B 32 153 122 96.6 24.4 32 
 
3 PRABU 32 M YES NO NO YES NO NO ALCOHOLIC A 24 168 160 88 32 48 
 
4 SAROJINI 45 F YES NO NO YES NO NO ALCOHOLIC B 36 144 123 86.4 24.6 33 
 
5 RAJAN 48 M YES NO NO YES NO NO HEPATITIS B A 13 178 154 110.2 30.8 37 
 
6 KAMALA 57 F YES NO NO YES NO NO HCC B 19 139 132 81.6 26.4 31 
 
7 RAMASAMY 39 M YES NO NO NO NO NO BUDD CHIARI SYNDROME A 23 176 156 105.8 31.2 39 
 
8 NAGAMMAL 63 F YES NO NO NO NO NO HEART FAILURE B 23 143 134 78.2 26.8 38 
 
9 MOHAN 23 M YES NO NO NO NO NO AUTOIMMUNE HEPATITIS A 24 159 154 83.2 30.8 45 
 
10 RAJ 20 M YES NO NO NO NO NO WILSONS DISEASE B 25 156 143 93.4 28.6 34 
 
11 SUNDARAM 42 M YES NO NO NO NO NO ALCOHOLIC A 21 162 160 83 32 47 
 
12 SHANKAR 54 M YES YES NO NO NO NO ALCOHOLIC A 32 176 162 101.6 32.4 42 
 
13 VADIVU 46 F YES YES NO NO NO NO ALCOHOLIC B 28 142 136 75.8 27.2 39 
 
14 VIJAYA 52 F YES YES NO NO NO NO NASH B 29 138 128 81.4 25.6 31 
 
15 AANANDHI 27 F YES YES NO NO NO NO CRYPTOGENIC A 10 169 156 96.8 31.2 41 
 
16 VENKATASAMY 39 M YES NO NO NO YES NO ALCOHOLIC B 23 149 137 91.6 27.4 30 
 
17 BALAN 60 M YES NO NO NO NO NO ALCOHOLIC B 28 150 138 93.4 27.6 29 
 
18 MAYILSAMY 61 M YES NO NO NO NO YES ALCOHOLIC C 42 128 89 88.2 17.8 22 DEATH 
19 KUMAR 48 M YES NO YES YES NO NO ALCOHOLIC C 30 130 102 81.6 20.4 28 
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20 SELVARAJ 59 M YES NO NO YES NO NO NASH B 31 145 134 81.2 26.8 37 
 
21 AYYASAMY 38 M YES NO YES NO NO NO ALCOHOLIC C 35 121 98 71.4 19.6 30 
 
22 JAMEELA 40 F YES NO NO NO YES NO ALCOHOLIC B 21 136 122 69.6 24.4 42 
 
23 PICHAIYAMMAL 51 F NO YES YES NO NO NO HEPATITIS B C 33 112 88 66.4 17.6 28 
 
24 SELVAKUMAR 47 M NO YES NO NO NO NO HEPATITIS C A 21 176 154 99.2 30.8 46 
 
25 PALANIYAMMAL 52 F NO YES YES NO NO NO ALCOHOLIC B 20 155 122 90.6 24.4 40 
 
26 MOSES 52 M YES YES YES NO YES NO ALCOHOLIC C 36 122 100 70 20 32 
 
27 SELVI 59 F YES YES NO NO NO NO NASH A 18 188 154 111.2 30.8 46 
 
28 MURUGESAN 47 M YES NO NO NO NO NO ALCOHOLIC B 19 164 133 98.4 26.6 39 
 
29 VASUKI 51 F YES NO NO NO NO NO ALCOHOLIC B 25 154 140 84 28 42 
 
30 RAMANAN 34 M YES NO YES NO NO NO ALCOHOLIC B 27 136 132 81.6 26.4 28 
 
31 KANNAN 61 M YES NO NO NO NO NO ALCOHOLIC A 21 177 158 97.4 31.6 48 
 
32 SURESH 54 M YES NO NO NO NO NO ALCOHOLIC A 22 167 156 85.8 31.2 50 
 
33 KUPPUSAMY 31 M YES YES NO NO NO NO PRIMARY BILIARY CIRRHOSIS A 24 156 152 83.6 30.4 42 
 
34 JAYARAJ 47 M YES NO YES NO YES NO ALCOHOLIC C 34 132 110 88 22 22 
 
35 MARY 45 F YES NO YES NO YES NO ALCOHOLIC C 36 124 92 79.6 18.4 26 
 
36 ANBALAGI 50 F YES NO YES NO NO NO ALCOHOLIC C 38 108 74 59.2 14.8 34 
 
37 GOPALAKRISHNAN 56 M NO NO NO NO NO NO ALCOHOLIC B 31 172 135 102 27 43 
 
38 SUBBATHAL 62 F YES NO NO NO NO NO HEART FAILURE B 22 149 141 84.8 28.2 36 
 
39 KRISHNAN 54 M YES NO NO NO NO NO ALCOHOLIC A 26 192 154 113.2 30.8 48 
 
40 LALITHA 54 F YES NO NO NO NO NO ALCOHOLIC A 22 210 152 140.6 30.4 39 
 
41 GANESAN 38 M YES NO NO YES NO NO ALCOHOLIC B 34 133 123 80.4 24.6 28 
 
42 KRISHNAVENI 46 F YES NO NO YES NO NO HEPATITIS B C 35 104 82 57.6 16.4 30 
 
43 ARUMUGAM 54 M YES NO NO YES NO NO ALCOHOLIC A 37 152 145 77 29 46 
 
44 MOHANRAJ 36 M YES YES YES YES NO YES ALCOHOLIC C 50 112 98 66.4 19.6 26 DEATH 
45 AYYANAR 32 M YES NO NO YES NO NO ALCOHOLIC C 33 132 86 86.8 17.2 28 
 
46 ALLWYN 54 M YES NO NO NO NO NO ALCOHOLIC B 24 148 136 78.8 27.2 42 
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47 ELANGO 61 M YES YES NO NO NO NO ALCOHOLIC A 32 176 156 104.8 31.2 40 
 
48 BALAJI 65 M YES NO NO NO NO NO NASH A 22 166 158 98.4 31.6 36 
 
49 GOPINATH 35 M YES NO NO NO YES NO ALCOHOLIC B 21 142 132 80.6 26.4 35 
 
50 PECHIYAMMAL 48 F YES NO NO NO NO NO ALCOHOLIC A 32 166 155 97 31 38 
 
51 PRAKASH 49 M YES NO NO YES NO NO ALCOHOLIC B 12 137 123 84.4 24.6 28 
 
52 MEGALA 51 F NO NO NO NO NO NO ALCOHOLIC A 32 188 145 113 29 46 
 
53 SANTHOSH 51 M YES NO NO NO NO NO HEPATITIS B C 43 132 102 75.6 20.4 36 
 
54 KUMARI 49 F YES NO NO NO NO NO ALCOHOLIC B 23 155 134 83.2 26.8 45 
 
55 KUMAR 41 M YES NO NO NO NO NO ALCOHOLIC C 25 114 93 63.4 18.6 32 
 
56 SUSEELA 46 F YES NO NO NO NO NO ALCOHOLIC B 27 137 122 75.6 24.4 37 
 
57 VINOTH 58 M YES NO NO NO NO NO ALCOHOLIC B 29 135 132 69.6 26.4 39 
 
58 SELVAMANI 51 M NO YES NO NO NO NO ALCOHOLIC A 20 183 152 108.6 30.4 44 
 
59 RAMASAMI 52 M NO YES NO NO NO NO ALCOHOLIC B 32 142 121 85.8 24.2 32 
 
60 VASANTH 47 M NO YES NO NO NO NO ALCOHOLIC A 30 187 154 114.2 30.8 42 
 
61 SURYA 48 M YES NO NO NO NO NO HEPATITIS B A 21 166 149 100.2 29.8 36 
 
62 MANIYAN 50 M YES NO NO NO NO NO ALCOHOLIC B 13 143 115 82 23 38 
 
63 JAYAPAL 50 M YES NO YES NO YES NO ALCOHOLIC C 26 102 74 65.2 14.8 22 
 
64 JAYACHANDRAN 53 M NO YES NO NO NO NO ALCOHOLIC A 10 160 136 89.8 27.2 43 
 
65 BALAKRISHNAN 39 M NO YES NO NO NO NO ALCOHOLIC B 13 130 112 75.6 22.4 32 
 
66 GOVINDHASAMY 43 M YES NO NO NO NO NO ALCOHOLIC A 15 178 143 101.4 28.6 48 
 
67 MENAKA 45 F NO YES YES NO NO NO ALCOHOLIC C 36 119 94 72.2 18.8 28 
 
68 MICHEAL 29 M NO NO NO NO NO NO ALCOHOLIC A 15 177 148 108.4 29.6 39 
 
69 ABIRAMI 50 F YES NO NO NO NO NO ALCOHOLIC B 24 154 121 94.8 24.2 35 
 
70 KOLAPPAN 52 M YES NO NO YES NO NO ALCOHOLIC B 26 142 118 81.4 23.6 37 
 
71 SIVABHAGYAM 48 F YES NO NO YES NO YES ALCOHOLIC C 34 123 96 73.8 19.2 30 
 
72 KALAISELVI 43 F YES NO NO NO NO NO NON ALCOHOLIC B 27 144 132 77.6 26.4 40 
 
73 RANI 46 F YES NO NO NO NO NO ALCOHOLIC A 21 178 157 94.6 31.4 52 
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74 RAJAMANI 38 M YES NO NO NO NO NO ALCOHOLIC B 22 152 138 83.4 27.6 41 
 
75 DEVI 61 F YES NO YES NO YES NO ALCOHOLIC C 41 125 84 71.2 16.8 37 
 
76 GIRIJA 47 M YES NO NO NO NO NO ALCOHOLIC A 15 171 143 96.4 28.6 46 
 
77 MARATHAL 47 F YES NO NO NO NO NO HEPATITIS B B 34 151 110 94 22 35 
 
78 PAULRAJ 24 M YES YES YES NO NO NO ALCOHOLIC& SICKLE CELL DISEASE C 26 129 90 85 18 26 
 
79 SUBBULAKSHMI 29 F YES NO NO NO NO NO EHPVO A 16 176 145 104 29 43 
 
80 AMAL 42 M NO YES YES NO NO NO ALCOHOLIC C 32 122 94 74.2 18.8 29 
 
81 ANTHONIYAMMAL 52 F YES NO NO NO NO NO ALCOHOLIC B 18 156 134 86.2 26.8 43 
 
82 ANTONY 38 M YES NO YES NO YES NO EHPVO C 35 133 102 79.6 20.4 33 
 
83 PAUL 45 M NO YES NO NO NO NO ALCOHOLIC A 24 187 132 115.6 26.4 45 
 
84 KIRISH 36 M YES NO NO NO NO NO ALCOHOLIC A 27 167 142 84.6 28.4 54 
 
85 KANNA 47 M NO YES NO NO NO NO ALCOHOLIC A 21 188 154 107.2 30.8 50 
 
86 ABDHUL 62 M YES NO NO NO NO NO ALCOHOLIC B 22 156 122 93.6 24.4 38 
 
87 JAFFER 61 M NO NO NO NO NO NO ALCOHOLIC B 36 165 126 104.8 25.2 35 
 
88 MARIYAPPAN 58 M YES NO NO NO NO NO HEART FAILURE A 14 188 158 114.4 31.6 42 
 
89 KANNAMAL 36 F YES NO NO NO NO NO ALCOHOLIC B 16 178 145 116 29 33 
 
90 CHELLAPAN 52 M YES NO NO NO NO NO ALCOHOLIC A 20 192 163 115.4 32.6 44 
 
91 CHELLAMAL 42 F YES NO NO NO NO NO CRYPTOGENIC B 24 163 129 109.2 25.8 28 
 
92 CHINNAPONNU 47 F YES NO YES NO YES NO ALCOHOLIC C 43 132 78 94.4 15.6 22 DEATH 
93 MOIDEEN 51 M YES NO NO NO NO NO ALCOHOLIC A 22 186 145 123 29 34 
 
94 PODHUMPONNU 45 F NO NO NO NO NO NO ALCOHOLIC B 32 165 136 107.8 27.2 30 
 
95 IBRAHIM 55 M YES NO NO YES NO NO ALCOHOLIC B 32 145 126 83.8 25.2 36 
 
96 RANGI 53 F NO NO NO NO NO NO ALCOHOLIC A 21 202 174 112.2 34.8 55 
 
97 RATHNA 46 F YES NO NO YES NO NO ALCOHOLIC A 12 179 167 91.6 33.4 54 
 
98 SATHYA 47 F YES NO NO NO NO NO CRYPTOGENIC B 23 134 137 72.6 27.4 34 
 
99 RAJALINGAM 46 M YES NO NO YES NO NO ALCOHOLIC C 33 122 112 75.6 22.4 24 
 
100 NANDHAN 51 M YES YES NO NO YES NO ALCOHOLIC B 24 154 143 83.4 28.6 42 
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101 KAMALAVENI 46 F YES NO NO YES NO NO NASH B 26 143 136 78.8 27.2 37 
 
102 KALIYAPAN 39 M NO YES NO NO NO NO ALCOHOLIC A 27 178 156 100.8 31.2 46 
 
103 SUBBATHAL 47 F YES NO NO YES NO NO ALCOHOLIC B 35 167 145 104 29 34 
 
104 MARATHAL 32 F NO YES NO NO NO NO _ A 10 188 158 107.4 31.6 49 
 
105 JAYASEELAN 48 M YES NO YES YES NO NO ALCOHOLIC C 36 134 89 92.2 17.8 24 
 
106 MUTHAMMAL 43 F NO YES NO NO NO NO _ A 23 176 125 98 25 53 
 
107 MANOJ 46 M YES YES NO NO NO NO ALCOHOLIC B 35 133 132 75.6 26.4 31 
 
108 KALA 53 F NO YES NO NO NO NO _ A 22 167 137 94.6 27.4 45 
 
109 MUTHUSAMY 57 M YES NO YES NO NO NO _ B 32 143 133 80.4 26.6 36 
 
110 PUSHPA 51 F YES NO NO YES NO NO ALCOHOLIC A 20 163 152 86.6 30.4 46 
 
111 TAMILARASAN 60 M YES NO YES YES YES NO ALCOHOLIC C 40 114 98 64.4 19.6 30 DEATH 
112 VIGNESH 61 M YES NO NO NO NO NO ALCOHOLIC B 26 139 124 74.2 24.8 40 
 
113 MOHAMMED HANIFA 56 M YES NO YES NO NO NO ALCOHOLIC C 35 109 83 60.4 16.6 32 
 
114 DHANDAPANI 49 M YES NO YES NO NO NO _ B 27 177 142 105.6 28.4 43 
 
115 MANIKKAM 46 M YES NO NO NO NO NO ALCOHOLIC A 18 187 154 102.2 30.8 54 
 
116 LIVINGSTON 36 M YES NO NO NO NO NO _ B 28 164 132 96.6 26.4 41 
 
117 SOUNDARAJAN 45 M YES NO NO NO NO NO ALCOHOLIC B 32 136 121 73.8 24.2 38 
 
118 LAKSHMI 52 F YES NO NO NO NO NO _ A 12 184 154 110.2 30.8 43 
 
119 NEELA 50 F YES YES YES NO NO NO ALCOHOLIC C 46 122 101 69.8 20.2 32 DEATH 
120 SARAVANAN 39 M YES NO NO NO NO NO ALCOHOLIC B 10 143 123 85.4 24.6 33 
 
 
 
